@NP	Olfactory ensheathing cells	1
@NP	GDNF	61
@NP	spinal cord repair Li Cao ,1 Li Liu	77
@NP	spinal cord repair Li Cao	77
@NP	,1 Li Liu	102
@NP	,1,2 Zhe-Yu Chen ,1 Li-Mei Wang	111
@NP	,1,2 Zhe-Yu Chen ,1	111
@NP	Li-Mei Wang	130
@NP	,1 Jun-Li	141
@NP	Ye ,1,2 Hai-Yan Qiu ,1,2 Chang-Lin Lu1	151
@NP	Ye	151
@NP	,1,2 Hai-Yan Qiu ,1,2 Chang-Lin Lu1	153
@NP	Cheng He1 1Department	196
@NP	Neurobiology	221
@NP	Second Military Medical University	235
@NP	Shanghai 200433	271
@NP	2Department	291
@NP	Pathophysiology	306
@NP	Qingdao Medical College of Qingdao University	323
@NP	Qingdao Medical College	323
@NP	Qingdao University	350
@NP	Shandong 266021 , China	370
@NP	Shandong 266021	370
@NP	China	387
@NP	Li Cao and Li Liu	394
@NP	the study Correspondence	435
@NP	Cheng He	464
@NP	Cheng	464
@NP	He	470
@NP	Department	474
@NP	Neurobiology	488
@NP	Second Military Medical University	502
@NP	Shanghai 200433	538
@NP	China E-mail	555
@NP	chenghe@online.sh.cn Summary Olfactory ensheathing cell -LRB- OEC -RRB-	569
@NP	chenghe@online.sh.cn	569
@NP	Summary Olfactory ensheathing cell -LRB- OEC -RRB-	591
@NP	Summary Olfactory ensheathing cell	591
@NP	OEC	627
@NP	transplantation	632
@NP	a very promising therapy for spinal cord repair	663
@NP	a very promising therapy	663
@NP	spinal cord repair	692
@NP	this study	715
@NP	we	727
@NP	the ability of genetically modified OECs	737
@NP	the ability	737
@NP	genetically modified OECs	752
@NP	high levels	789
@NP	glial cell	804
@NP	neurotrophic factor -LRB- GDNF -RRB-	827
@NP	neurotrophic factor	827
@NP	GDNF	848
@NP	spinal cord repair	865
@NP	The GDNF gene	885
@NP	OECs using a retroviral-based system	919
@NP	OECs	919
@NP	a retroviral-based system	930
@NP	The engineered OECs	957
@NP	their ability to express and secrete biologically active GDNF in vitro	1005
@NP	biologically active GDNF	1042
@NP	implantation	1083
@NP	the spinal cord of adult rats with complete spinal cord transection	1101
@NP	the spinal cord	1101
@NP	adult rats with complete spinal cord transection	1120
@NP	adult rats	1120
@NP	complete spinal cord transection	1136
@NP	OEC survival and GDNF production	1170
@NP	OEC survival	1170
@NP	GDNF production	1187
@NP	The locomotor functions of animals	1218
@NP	The locomotor functions	1218
@NP	animals	1245
@NP	axon regeneration	1271
@NP	the morphological level	1306
@NP	our knowledge	1334
@NP	we	1349
@NP	the first time	1363
@NP	the genetically modified OECs	1383
@NP	GDNF in vivo	1438
@NP	GDNF	1438
@NP	vivo	1446
@NP	recovery	1476
@NP	spinal cord injury -LRB- SCI -RRB-	1491
@NP	spinal cord injury	1491
@NP	SCI	1511
@NP	This work	1517
@NP	the outgrowthpromoting property of OECs	1536
@NP	the outgrowthpromoting property	1536
@NP	OECs	1571
@NP	the neuroprotective effects of the	1581
@NP	the neuroprotective effects	1581
@NP	the	1612
@NP	neurotrophic factors	1643
@NP	new avenues	1674
@NP	the treatment of SCI	1690
@NP	the treatment	1690
@NP	SCI	1707
@NP	October 23 , 2003 Accepted October 24 , 2003	2389
@NP	October 23 , 2003	2389
@NP	October 24 , 2003	2415
@NP	Advanced Access publication December 22	2433
@NP	Advanced Access publication	2433
@NP	December 22	2461
@NP	2003 Introduction Spinal cord injury	2474
@NP	2003 Introduction	2474
@NP	Spinal cord injury	2494
@NP	SCI	2514
@NP	one of the most devastating forms of trauma experienced by humans	2522
@NP	one	2522
@NP	the most devastating forms of trauma experienced by humans	2529
@NP	the most devastating forms	2529
@NP	trauma experienced by humans	2559
@NP	trauma	2559
@NP	humans	2581
@NP	Approximately half of the patients	2589
@NP	Approximately half	2589
@NP	the patients	2611
@NP	complete cord injury	2629
@NP	no preservation of voluntary motor	2655
@NP	no preservation	2655
@NP	voluntary motor	2674
@NP	sensory function below the level of injury -LRB- Tator et al. , 1990 -RRB-	2693
@NP	sensory function	2693
@NP	the level of injury -LRB- Tator et al. , 1990 -RRB-	2716
@NP	the level	2716
@NP	injury -LRB- Tator et al. , 1990 -RRB-	2729
@NP	injury	2729
@NP	Tator	2737
@NP	et al. , 1990	2743
@NP	et al.	2743
@NP	1990	2751
@NP	Development of powerful strategies to treat SCI	2758
@NP	Development	2758
@NP	powerful strategies	2773
@NP	SCI	2802
@NP	a major clinical challenge	2815
@NP	recent dramatic progress	2852
@NP	cellular transplantation , gene therapy and molecular treatment	2880
@NP	cellular transplantation	2880
@NP	gene therapy	2906
@NP	molecular treatment	2923
@NP	the optimism	2958
@NP	future cures for such injuries	2977
@NP	future cures	2977
@NP	such injuries	2994
@NP	Grill	3009
@NP	et al. , 1997a , b	3015
@NP	et al.	3015
@NP	1997a	3023
@NP	b	3030
@NP	Giehl et al. , 1997	3033
@NP	Giehl	3033
@NP	et al. , 1997	3039
@NP	et al.	3039
@NP	1997	3047
@NP	Li et al. , 1997	3053
@NP	Li	3053
@NP	et al. , 1997	3056
@NP	et al.	3056
@NP	1997	3064
@NP	Rapalino et al. , 1998	3070
@NP	Rapalino	3070
@NP	et al. , 1998	3079
@NP	et al.	3079
@NP	1998	3087
@NP	Jones et al. , 2001	3093
@NP	Jones	3093
@NP	et al. , 2001	3099
@NP	et al.	3099
@NP	2001	3107
@NP	Blits et al. , 2002	3113
@NP	Blits	3113
@NP	et al. , 2002	3119
@NP	et al.	3119
@NP	2002	3127
@NP	Schwab , 2002	3133
@NP	Schwab	3133
@NP	2002	3141
@NP	Olfactory ensheathing cells -LRB- OECs -RRB-	3148
@NP	Olfactory ensheathing cells	3148
@NP	OECs	3177
@NP	growing axons	3190
@NP	neurons of the nasal cavity	3209
@NP	neurons	3209
@NP	the nasal cavity	3220
@NP	the olfactory bulb of the brain and form synapses	3266
@NP	the olfactory bulb	3266
@NP	the brain and form synapses	3288
@NP	second-order neurons -LRB- Doucette , 1984 -RRB-	3321
@NP	second-order neurons	3321
@NP	Doucette	3343
@NP	1984	3353
@NP	Recent studies	3360
@NP	implantation of rodent and human OECs	3391
@NP	implantation	3391
@NP	rodent and human OECs	3407
@NP	one	3443
@NP	the most promising strategies	3450
@NP	longdistance regeneration	3491
@NP	the injured spinal cord	3520
@NP	Li	3545
@NP	et al. , 1997	3548
@NP	et al.	3548
@NP	1997	3556
@NP	Barnett et al. , 2000	3562
@NP	Barnett	3562
@NP	et al. , 2000	3570
@NP	et al.	3570
@NP	2000	3578
@NP	Kato et al. , 2000	3584
@NP	Kato	3584
@NP	et al. , 2000	3589
@NP	et al.	3589
@NP	2000	3597
@NP	Ramon-Cueto et al. , 2000	3603
@NP	Ramon-Cueto	3603
@NP	et al. , 2000	3615
@NP	et al.	3615
@NP	2000	3623
@NP	the number of axons that regrow and reconnect	3634
@NP	the number	3634
@NP	axons that regrow and reconnect	3648
@NP	axons	3648
@NP	Gudino-Cabrera et al. , 2000	3703
@NP	Gudino-Cabrera	3703
@NP	et al.	3718
@NP	2000	3726
@NP	Neurotrophic factors	3733
@NP	critical mediators of neuronal survival and nerve fibre outgrowth	3784
@NP	critical mediators	3784
@NP	neuronal survival and nerve fibre outgrowth	3806
@NP	development	3857
@NP	The beneficial effects	3870
@NP	neurotrophic factors on neuronal protection and repair in the CNS	3896
@NP	neurotrophic factors	3896
@NP	neuronal protection and repair	3920
@NP	the CNS	3954
@NP	Tuszynski , 1999 ; Jones et al. , 2001	3989
@NP	Tuszynski	3989
@NP	1999 ; Jones et al.	4000
@NP	1999	4000
@NP	Jones et al.	4006
@NP	Jones	4006
@NP	et al.	4012
@NP	2001	4020
@NP	more than 30 neurotrophic factors	4036
@NP	fewer than six of them	4081
@NP	fewer than six	4081
@NP	them	4099
@NP	potential treatments	4130
@NP	lesioned spinal cords in the animal model -LRB- Schwab , 2002 -RRB-	4155
@NP	lesioned spinal cords	4155
@NP	the animal model -LRB- Schwab , 2002 -RRB-	4180
@NP	the animal model	4180
@NP	Schwab	4198
@NP	2002	4206
@NP	Brain-derived neurotrophic factor and neurotrophin-3	4213
@NP	Brain-derived neurotrophic factor	4213
@NP	neurotrophin-3	4251
@NP	they	4312
@NP	a role	4322
@NP	regeneration	4342
@NP	spinal motor pathways	4358
@NP	Jones	4381
@NP	et al. , 2001 ; Liu et al. , 2002 ; Tuszynski et al. , 2003 ; Zhou et al. , 2003	4387
@NP	et al. , 2001	4387
@NP	et al.	4387
@NP	2001	4395
@NP	Liu et al. , 2002	4401
@NP	Liu	4401
@NP	et al. , 2002	4405
@NP	et al.	4405
@NP	2002	4413
@NP	Tuszynski et al. , 2003	4419
@NP	Tuszynski	4419
@NP	et al. , 2003	4429
@NP	et al.	4429
@NP	2003	4437
@NP	Zhou et al. , 2003	4443
@NP	Zhou	4443
@NP	et al. , 2003	4448
@NP	et al.	4448
@NP	2003	4456
@NP	Brain-derived neurotrophic factor	4463
@NP	rubrospinal tract -LRB- RST -RRB- regeneration	4521
@NP	rubrospinal tract -LRB- RST -RRB-	4521
@NP	rubrospinal tract	4521
@NP	RST	4540
@NP	regeneration	4545
@NP	limited effects on corticospinal tract -LRB- CST -RRB-	4567
@NP	limited effects	4567
@NP	corticospinal tract -LRB- CST -RRB-	4586
@NP	corticospinal tract	4586
@NP	CST	4607
@NP	regeneration -LRB- Schnell et al. , 1994 ; Tetzlaff et al. , 1994 -RRB-	4612
@NP	regeneration	4612
@NP	Schnell	4626
@NP	et al. , 1994 ; Tetzlaff et al. , 1994	4634
@NP	et al.	4634
@NP	1994 ; Tetzlaff et al.	4642
@NP	1994	4642
@NP	Tetzlaff et al.	4648
@NP	Tetzlaff	4648
@NP	et al.	4657
@NP	1994	4665
@NP	Neurotrophin-3	4672
@NP	the growth of corticospinal axons	4720
@NP	the growth	4720
@NP	corticospinal axons	4734
@NP	spinal cord injury	4760
@NP	the death of some corticospinal neurons -LRB- Giehl et al. , 2001 -RRB-	4807
@NP	the death	4807
@NP	some corticospinal neurons -LRB- Giehl et al. , 2001 -RRB-	4820
@NP	some corticospinal neurons	4820
@NP	Giehl	4848
@NP	et al. , 2001	4854
@NP	et al.	4854
@NP	2001	4862
@NP	More recent studies	4869
@NP	removal of NT-3 or blocking TrkC activity	4904
@NP	removal	4904
@NP	NT-3 or blocking TrkC activity	4915
@NP	NT-3	4915
@NP	TrkC activity	4932
@NP	myelination	4960
@NP	Schwann cells	4975
@NP	functional recovery -LRB- Chan et al. , 2001 ; Cosgaya et al. , 2002 -RRB-	5030
@NP	functional recovery	5030
@NP	Chan	5051
@NP	et al. , 2001 ; Cosgaya et al. , 2002	5056
@NP	et al.	5056
@NP	2001 ; Cosgaya et al.	5064
@NP	2001	5064
@NP	Cosgaya et al.	5070
@NP	Cosgaya	5070
@NP	et al.	5078
@NP	2002	5086
@NP	The glial cell line-derived neurotrophic factor -LRB- GDNF -RRB-	5093
@NP	The glial cell	5093
@NP	line-derived neurotrophic factor -LRB- GDNF -RRB-	5108
@NP	line-derived neurotrophic factor	5108
@NP	GDNF	5142
@NP	a trophic factor for midbrain dopaminergic neurons -LRB- Lin et al. , 1993 -RRB-	5174
@NP	a trophic factor	5174
@NP	midbrain dopaminergic neurons -LRB- Lin et al. , 1993 -RRB-	5195
@NP	midbrain dopaminergic neurons	5195
@NP	Lin	5226
@NP	et al. , 1993	5230
@NP	et al.	5230
@NP	1993	5238
@NP	the most potent trophic factor	5266
@NP	motoneurons	5301
@NP	Henderson et al. , 1994 ; Li et al. , 1995 ; Oppenheim et al. , 1995	5314
@NP	Henderson	5314
@NP	et al. , 1994 ; Li et al. , 1995 ; Oppenheim et al. , 1995	5324
@NP	et al. , 1994	5324
@NP	et al.	5324
@NP	1994	5332
@NP	Li et al. , 1995	5338
@NP	Li	5338
@NP	et al. , 1995	5341
@NP	et al.	5341
@NP	1995	5349
@NP	Oppenheim et al. , 1995	5355
@NP	Oppenheim	5355
@NP	et al. , 1995	5365
@NP	et al.	5365
@NP	1995	5373
@NP	Fibroblasts expressing GDNF	5380
@NP	Fibroblasts	5380
@NP	GDNF	5403
@NP	axon elongation	5438
@NP	primary cultured cortical neurons -LRB- Paratcha et al. , 2003 -RRB-	5457
@NP	primary	5457
@NP	cortical neurons -LRB- Paratcha et al. , 2003 -RRB-	5474
@NP	cortical neurons	5474
@NP	Paratcha	5492
@NP	et al. , 2003	5501
@NP	et al.	5501
@NP	2003	5509
@NP	a similar culture system	5519
@NP	cortical neurons	5545
@NP	a monolayer of fibroblasts	5573
@NP	a monolayer	5573
@NP	fibroblasts	5588
@NP	brain-derived neurotrophic factor	5611
@NP	a great number of shorter and more branching neurites	5667
@NP	a great number	5667
@NP	shorter and more branching neurites	5685
@NP	GDNF	5738
@NP	a more potent effect	5752
@NP	axonal growth	5788
@NP	these cells -LRB- Paratcha et al. , 2003 -RRB-	5805
@NP	these cells	5805
@NP	Paratcha	5818
@NP	et al. , 2003	5827
@NP	et al.	5827
@NP	2003	5835
@NP	GDNF	5855
@NP	motor axon outgrowth	5879
@NP	the surrounding white matter	5907
@NP	the organotypic spinal cord culture model -LRB- Ho et al. , 2000 -RRB-	5939
@NP	the organotypic spinal cord culture model	5939
@NP	Ho	5982
@NP	et al. , 2000	5985
@NP	et al.	5985
@NP	2000	5993
@NP	the spinal cord	6018
@NP	GDNF	6035
@NP	a trophic effect	6058
@NP	corticospinal neurons	6078
@NP	longterm survival	6112
@NP	axotomy -LRB- Giehl et al. , 1997 -RRB-	6136
@NP	axotomy	6136
@NP	Giehl	6145
@NP	et al. , 1997	6151
@NP	et al.	6151
@NP	1997	6159
@NP	GDNF	6176
@NP	behavioural and anatomical neuroprotection	6214
@NP	SCI -LRB- Watabe et al. , 2000 ; Cheng et al. , 2002 -RRB-	6267
@NP	SCI	6267
@NP	Watabe	6272
@NP	et al. , 2000 ; Cheng et al. , 2002	6279
@NP	et al.	6279
@NP	2000 ; Cheng et al.	6287
@NP	2000	6287
@NP	Cheng et al.	6293
@NP	Cheng	6293
@NP	et al.	6299
@NP	2002	6307
@NP	Injections and pumps	6314
@NP	neurotrophic factors	6358
@NP	the lesion site	6382
@NP	these methods	6408
@NP	long-term , localized , high-dose neurotrophic factor delivery	6437
@NP	An alternative approach	6499
@NP	long-term and site-specific delivery of neurotrophic factors	6537
@NP	long-term and site-specific delivery	6537
@NP	neurotrophic factors	6577
@NP	the injured spinal cord	6601
@NP	ex vivo gene therapy -LRB- Tuszynski , 1997 -RRB-	6628
@NP	ex vivo gene therapy	6628
@NP	Tuszynski	6650
@NP	1997	6661
@NP	Schwann cells , fibroblasts and intercostal nerve grafts	6668
@NP	Schwann cells	6668
@NP	fibroblasts	6683
@NP	intercostal nerve grafts	6699
@NP	neurotrophic factors	6758
@NP	Grill	6799
@NP	et al. , 1997	6805
@NP	et al.	6805
@NP	1997	6813
@NP	Menei et al. , 1998	6819
@NP	Menei	6819
@NP	et al. , 1998	6825
@NP	et al.	6825
@NP	1998	6833
@NP	Tuszynski et al. , 1998	6839
@NP	Tuszynski	6839
@NP	et al. , 1998	6849
@NP	et al.	6849
@NP	1998	6857
@NP	Blits et al. , 1999 , 2000	6863
@NP	Blits	6863
@NP	et al. , 1999 , 2000	6869
@NP	et al.	6869
@NP	1999	6877
@NP	2000	6883
@NP	Liu et al. , 1999a , b	6889
@NP	Liu	6889
@NP	et al. , 1999a , b	6893
@NP	et al.	6893
@NP	1999a	6901
@NP	b	6908
@NP	Blesch et al. , 2001	6911
@NP	Blesch	6911
@NP	et al. , 2001	6918
@NP	et al.	6918
@NP	2001	6926
@NP	These studies	6933
@NP	various axonal populations	6980
@NP	most cases	7015
@NP	the majority of regenerating axons	7027
@NP	the majority	7027
@NP	regenerating axons	7043
@NP	the transplant	7083
@NP	few fibres	7102
@NP	the site of injury	7133
@NP	the site	7133
@NP	injury	7145
@NP	Implants of OECs	7153
@NP	Implants	7153
@NP	OECs	7165
@NP	neurotrophic factor delivery	7188
@NP	this	7223
@NP	axons	7260
@NP	the distal part	7278
@NP	the spinal cord -LRB- Li et al. , 1997 ; Ramon-Cueto et al. , 2000 -RRB-	7297
@NP	the spinal cord	7297
@NP	Li	7314
@NP	et al. , 1997 ; Ramon-Cueto et al. , 2000	7317
@NP	et al.	7317
@NP	1997 ; Ramon-Cueto et al.	7325
@NP	1997	7325
@NP	Ramon-Cueto et al.	7331
@NP	Ramon-Cueto	7331
@NP	et al.	7343
@NP	2000	7351
@NP	the use	7382
@NP	genetically engineered fibroblasts	7393
@NP	origin	7450
@NP	The feasibility	7485
@NP	genetically modified OECs	7518
@NP	the intact and injured spinal cord	7549
@NP	Ruitenberg and colleagues	7613
@NP	Ruitenberg et al. , 2002	7640
@NP	Ruitenberg	7640
@NP	et al.	7651
@NP	2002	7659
@NP	upgrading	7677
@NP	the growth-promoting properties	7690
@NP	OEC by having them secrete additional neurotrophic factors	7725
@NP	OEC	7725
@NP	them	7739
@NP	additional neurotrophic factors	7752
@NP	a valuable strategy	7791
@NP	spinal cord repair -LRB- Blits et al. , 2002 ; Ruitenberg et al. , 2002 -RRB-	7825
@NP	spinal cord repair	7825
@NP	Blits et al. , 2002 ; Ruitenberg et al. , 2002	7845
@NP	Blits	7845
@NP	et al. , 2002 ; Ruitenberg et al. , 2002	7851
@NP	et al. , 2002	7851
@NP	et al.	7851
@NP	2002	7859
@NP	Ruitenberg et al. , 2002	7865
@NP	Ruitenberg	7865
@NP	et al. , 2002	7876
@NP	et al.	7876
@NP	2002	7884
@NP	limited neurotrophic factor expression of OECs	7897
@NP	limited neurotrophic factor expression	7897
@NP	OECs	7939
@NP	Boruch	7963
@NP	et al. , 2001 ; Woodhall et al. , 2001	7970
@NP	et al.	7970
@NP	2001 ; Woodhall et al.	7978
@NP	2001	7978
@NP	Woodhall et al.	7984
@NP	Woodhall	7984
@NP	et al.	7993
@NP	2001	8001
@NP	the present study	8011
@NP	we	8030
@NP	the ability of genetically modi ®	8040
@NP	the ability	8040
@NP	genetically modi ®	8055
@NP	OECs	8075
@NP	a high level of GDNF	8091
@NP	a high level	8091
@NP	GDNF	8107
@NP	spinal cord repair	8132
@NP	The GDNF gene	8152
@NP	OECs using a retroviral system	8186
@NP	OECs	8186
@NP	a retroviral system	8197
@NP	The engineered OECs	8218
@NP	® rst	8243
@NP	their ability to express and secrete biologically active GDNF in vitro	8265
@NP	biologically active GDNF	8302
@NP	implantation	8343
@NP	the spinal cord of adult rats with complete spinal cord transection	8361
@NP	the spinal cord	8361
@NP	adult rats with complete spinal cord transection	8380
@NP	adult rats	8380
@NP	complete spinal cord transection	8396
@NP	OEC survival and GDNF production	8430
@NP	OEC survival	8430
@NP	GDNF production	8447
@NP	The locomotor functions of animals	8478
@NP	The locomotor functions	8478
@NP	animals	8505
@NP	axon regeneration	8532
@NP	the morphological level	8567
@NP	our knowledge	8595
@NP	we	8610
@NP	the first time	8624
@NP	the genetically modified OECs	8644
@NP	GDNF in vivo	8699
@NP	GDNF	8699
@NP	vivo	8707
@NP	recovery	8737
@NP	SCI	8752
@NP	Materials and methods	8758
@NP	Materials	8758
@NP	methods	8772
@NP	Primary culture and purification	8780
@NP	OECs	8816
@NP	Primary olfactory bulb cultures	8821
@NP	adult Sprague ± Dawley rats	8870
@NP	2.5 months	8898
@NP	The modified protocol of Ramon - Cueto and colleagues	8915
@NP	The modified protocol of Ramon	8915
@NP	The modified protocol	8915
@NP	Ramon	8940
@NP	Cueto and colleagues	8947
@NP	Cueto	8947
@NP	colleagues	8957
@NP	Ramon-Cueto	8969
@NP	et al. , 1998	8981
@NP	et al.	8981
@NP	1998	8989
@NP	Brie ¯ y	9005
@NP	the olfactory nerve layer	9013
@NP	the rest of the olfactory bulb	9060
@NP	the rest	9060
@NP	the olfactory bulb	9072
@NP	0.25 % trypsin and 0.03 % collagenase	9114
@NP	0.25 % trypsin	9114
@NP	0.03 % collagenase	9132
@NP	0.03 %	9132
@NP	collagenase	9138
@NP	37 °C for 30 min	9167
@NP	37 °C	9167
@NP	30 min	9176
@NP	The cells	9184
@NP	D/F12 ±	9216
@NP	10 % fetal bovine serum	9222
@NP	uncoated dishes	9273
@NP	each for 12 h at 37 °C in 5 % CO2	9296
@NP	each	9296
@NP	12 h at 37 °C in 5 % CO2	9305
@NP	12 h	9305
@NP	37 °C in 5 % CO2	9313
@NP	37 °C	9313
@NP	5 % CO2	9321
@NP	The cell suspension	9328
@NP	5 µl -LRB- approximately 300 000 cells -RRB-	9366
@NP	5 µl	9366
@NP	approximately 300 000 cells	9372
@NP	100 mm Petri dishes	9415
@NP	45 min at 37 °C in 5 % CO2	9439
@NP	45 min	9439
@NP	37 °C in 5 % CO2	9449
@NP	37 °C	9449
@NP	5 % CO2	9457
@NP	These dishes	9465
@NP	anti-rabbit immunoglobulin G antibody	9503
@NP	1.5 µg polyclonal rabbit p-75 NGFR antibody	9542
@NP	1.5 µg	9542
@NP	polyclonal rabbit p-75 NGFR antibody	9549
@NP	Santa Cruz Biotechnology	9587
@NP	12 h at 4 °C	9618
@NP	12 h	9618
@NP	4 °C	9626
@NP	phosphatebuffered saline -LRB- PBS -RRB-	9644
@NP	phosphatebuffered saline	9644
@NP	PBS	9670
@NP	± 5 %	9674
@NP	bovine serum albumin	9678
@NP	4 h at room temperature	9703
@NP	4 h	9703
@NP	room temperature	9710
@NP	PBS	9728
@NP	the dishes	9749
@NP	each step	9766
@NP	Unbound cells	9777
@NP	the attached cells	9811
@NP	a cell scraper	9851
@NP	25	9909
@NP	mm2 ¯	9912
@NP	D/F12 ±	9942
@NP	10 % fetal bovine serum containing as mitogen 2 µM forskolin -LRB- Sigma -RRB-	9948
@NP	10 % fetal bovine serum	9948
@NP	mitogen 2 µM forskolin	9985
@NP	Sigma	10009
@NP	20 µg/ml	10020
@NP	Sigma	10048
@NP	The purity of the cultured OECs	10056
@NP	The purity	10056
@NP	the cultured OECs	10070
@NP	the	10070
@NP	OECs	10083
@NP	the number of Hoechst-labelled nuclei	10116
@NP	the number	10116
@NP	Hoechst-labelled nuclei	10130
@NP	the number of p-75 NGFR immunoreactive cells	10159
@NP	the number	10159
@NP	p-75 NGFR immunoreactive cells	10173
@NP	a microscope	10210
@NP	Retroviral preparation and infection of OECs The cDNA encoding rat preproGDNF	10224
@NP	Retroviral preparation and infection	10224
@NP	OECs The cDNA encoding rat preproGDNF	10264
@NP	OECs The cDNA	10264
@NP	OECs	10264
@NP	The cDNA	10269
@NP	rat preproGDNF	10287
@NP	the RTPCR method	10324
@NP	total RNA extracted from rat brain	10346
@NP	total RNA	10346
@NP	rat brain	10371
@NP	Specific primers	10382
@NP	forward	10400
@NP	5	10409
@NP	GGAAGCTTATGAAGTTATGGGATGTCG-3	10412
@NP	reverse , 5 ` - GAGGATCCTCAGATACATCCACACC-3 `	10444
@NP	reverse	10444
@NP	5	10453
@NP	GAGGATCCTCAGATACATCCACACC-3	10457
@NP	PCR	10491
@NP	preproGDNF cDNA that yielded 652 bp amplified products	10520
@NP	preproGDNF cDNA	10520
@NP	652 bp	10549
@NP	products	10566
@NP	GDNF cDNA	10581
@NP	U3 area	10609
@NP	repeat -LRB- LTR -RRB-	10641
@NP	repeat	10641
@NP	LTR	10649
@NP	the replication-defective recombinant retroviral pN2A	10657
@NP	Hantzopoulos	10712
@NP	et al. , 1989	10725
@NP	et al.	10725
@NP	1989	10733
@NP	EcoRV and BamHI enzyme	10742
@NP	pN2A-GDNF	10772
@NP	Fig. 1	10796
@NP	the unique feature of this double-copy vector	10804
@NP	the unique feature	10804
@NP	this double-copy vector	10826
@NP	gene	10873
@NP	the 3	10890
@NP	LTR	10898
@NP	duplication and transfer to the 5 `	10916
@NP	duplication	10916
@NP	transfer	10932
@NP	the 5	10944
@NP	LTR in infected cells , which can improve the expression of	10951
@NP	LTR	10951
@NP	infected cells , which can improve the expression of	10958
@NP	infected cells	10958
@NP	the expression of	10992
@NP	the expression	10992
@NP	genes	11021
@NP	The construct	11028
@NP	restriction analysis and sequencing	11059
@NP	Lipofectamine -LRB- Gibco -RRB-	11096
@NP	Lipofectamine	11096
@NP	Gibco	11111
@NP	pN2A-GDNF	11127
@NP	the packaging cell line , PA317 -LRB- Miller and Buttimore , 1986 -RRB-	11159
@NP	the packaging cell line	11159
@NP	PA317	11184
@NP	Miller and Buttimore	11191
@NP	1986	11213
@NP	The neomycin analogue G418	11220
@NP	resistant colonies	11267
@NP	Viral supernatants from these colonies	11287
@NP	Viral supernatants	11287
@NP	these colonies	11311
@NP	NIH 3T3 cells as described previously -LRB- Whittemore et al. , 1994 -RRB-	11341
@NP	NIH 3T3 cells	11341
@NP	Whittemore	11380
@NP	et al. , 1994	11391
@NP	et al.	11391
@NP	1994	11399
@NP	The cell line -LRB- PA317-GDNF2 -RRB-	11406
@NP	The cell line	11406
@NP	PA317-GDNF2	11421
@NP	the highest titre -LRB- 8 3 104 colony-forming units/ml -RRB-	11439
@NP	the highest titre	11439
@NP	8 3 104 colony-forming units/ml	11458
@NP	8	11458
@NP	3 104 colony-forming units/ml	11460
@NP	3 104	11460
@NP	colony-forming units/ml	11466
@NP	the purified adult rat	11510
@NP	primary OECs	11533
@NP	The most effective method for infecting dividing OECs	11547
@NP	The most effective method	11547
@NP	OECs	11596
@NP	a 2 h pretreatment	11605
@NP	8 pg/ml polybrene	11629
@NP	overnight infection	11659
@NP	the recombinant retrovirus in medium	11684
@NP	the recombinant retrovirus	11684
@NP	medium	11714
@NP	mitogens	11732
@NP	The same procedure	11742
@NP	the next day	11774
@NP	polybrene	11792
@NP	only l h.	11816
@NP	l	11821
@NP	Four to five days	11826
@NP	the last infection	11850
@NP	the OECs	11870
@NP	200 mg/ml G418	11898
@NP	the selected population	11919
@NP	a stable manner	11956
@NP	the cells	11973
@NP	the same selection medium	12003
@NP	a maximum total number of passages of six or seven	12035
@NP	a maximum total number	12035
@NP	passages of six or seven	12061
@NP	passages	12061
@NP	six or seven	12073
@NP	enough OECs	12098
@NP	experiments	12114
@NP	Characterization	12127
@NP	GDNF OECs Primary cultures	12147
@NP	adult rat normal OECs and GDNF OECs	12177
@NP	10 min with 4 % paraformaldehyde	12228
@NP	10 min	12228
@NP	4 % paraformaldehyde	12240
@NP	PBS	12278
@NP	1 % bovine serum albumin	12300
@NP	30 min	12328
@NP	the cultures	12336
@NP	4 °C	12377
@NP	the rabbit polyclonal antihuman GDNF antibody -LRB- 1/200 ; Promega -RRB-	12386
@NP	the rabbit	12386
@NP	polyclonal antihuman GDNF antibody -LRB- 1/200 ; Promega -RRB-	12397
@NP	polyclonal antihuman GDNF antibody	12397
@NP	1/200 ; Promega	12433
@NP	1/200	12433
@NP	Promega	12440
@NP	anti-p75NGFR rabbit antibody -LRB- 5 pg/ml , Santa Cruz Biotechnology -RRB-	12450
@NP	anti-p75NGFR rabbit antibody	12450
@NP	5 pg/ml , Santa Cruz Biotechnology	12480
@NP	5 pg/ml	12480
@NP	Santa Cruz Biotechnology	12489
@NP	monoclonal mouse	12516
@NP	anti-glial fibrillary acidic protein -LRB- GFAP -RRB-	12533
@NP	anti-glial fibrillary acidic protein	12533
@NP	GFAP	12571
@NP	1 : 1000 ; Sigma	12578
@NP	1 : 1000	12578
@NP	Sigma	12588
@NP	anti- S-100 mouse antibody -LRB- 1 : 2000 ; Sigma -RRB-	12599
@NP	anti- S-100 mouse antibody	12599
@NP	1 : 2000 ; Sigma	12627
@NP	1 : 2000	12627
@NP	Sigma	12637
@NP	PBS	12655
@NP	1 % bovine serum albumin	12670
@NP	The next day	12695
@NP	the cultures	12708
@NP	PBS	12742
@NP	40 min	12769
@NP	37 °C	12779
@NP	¯ uorescein isothiocyanate-labelled secondary antibodies -LRB- Promega -RRB-	12789
@NP	¯ uorescein isothiocyanate-labelled secondary antibodies	12789
@NP	¯ uorescein	12789
@NP	Promega	12846
@NP	They	12856
@NP	an Olympus BX-50 ¯ uorescence microscope	12896
@NP	Assay of GDNF production The amount of GDNF secreted by GDNF OECs	12937
@NP	Assay	12937
@NP	GDNF production The amount of GDNF secreted by GDNF OECs	12946
@NP	GDNF production	12946
@NP	The amount of GDNF	12962
@NP	The amount	12962
@NP	GDNF	12976
@NP	GDNF OECs	12993
@NP	enzyme-linked immunosorbent assay -LRB- ELISA -RRB-	13019
@NP	enzyme-linked immunosorbent assay	13019
@NP	ELISA	13054
@NP	the GDNF Emax ImmunoAssay System -LRB- Promega -RRB-	13067
@NP	the GDNF Emax ImmunoAssay System	13067
@NP	Promega	13101
@NP	the manufacturer 's instructions	13124
@NP	the manufacturer 's	13124
@NP	the ELISA plates -LRB- 96 wells -RRB-	13157
@NP	the ELISA plates	13157
@NP	96 wells	13175
@NP	an anti-GDNF monoclonal antibody -LRB- pH 8.2 -RRB-	13202
@NP	an anti-GDNF monoclonal antibody	13202
@NP	pH 8.2	13236
@NP	overnight at 4 ± 8 °C	13244
@NP	overnight	13244
@NP	4 ± 8 °C	13257
@NP	4 ±	13257
@NP	8 °C	13259
@NP	Plates	13264
@NP	1 h at room temperature	13293
@NP	1 h	13293
@NP	room temperature	13300
@NP	buffer	13331
@NP	GDNF standards ranging from 0 to 1000 pg/ml	13339
@NP	GDNF standards	13339
@NP	0	13367
@NP	1000 pg/ml	13372
@NP	recombinant GDNF	13403
@NP	Conditioned medium -LRB- CM -RRB-	13421
@NP	Conditioned medium	13421
@NP	CM	13441
@NP	2 x 106 cells in 2 ml medium	13464
@NP	2	13464
@NP	106 cells in 2 ml medium	13468
@NP	106 cells	13468
@NP	2 ml medium	13481
@NP	only 1 % fetal bovine serum for 24 h	13503
@NP	only 1 % fetal bovine serum	13503
@NP	24 h	13534
@NP	the wells -LRB- 100 µl -RRB- undiluted or diluted	13554
@NP	the wells -LRB- 100 µl -RRB-	13554
@NP	the wells	13554
@NP	100 µl	13565
@NP	1 : 10 or 1 : 100	13594
@NP	1 : 10	13594
@NP	1 : 100	13604
@NP	Samples and standards	13613
@NP	room temperature for 6 h on a shaker	13653
@NP	room temperature	13653
@NP	6 h on a shaker	13674
@NP	6 h	13674
@NP	a shaker	13681
@NP	The plate	13691
@NP	chicken anti-human GDNF polyclonal antibody	13738
@NP	chicken anti-human GDNF	13738
@NP	polyclonal antibody	13762
@NP	4 °C , horseradish peroxidase -LRB- HRP -RRB-	13795
@NP	4 °C	13795
@NP	horseradish peroxidase -LRB- HRP -RRB-	13800
@NP	horseradish peroxidase	13800
@NP	HRP	13824
@NP	antichicken antibody -LRB- 1 : 5000 -RRB-	13840
@NP	antichicken antibody	13840
@NP	1 : 5000	13862
@NP	1	13862
@NP	5000	13866
@NP	room temperature for 2 h	13875
@NP	room temperature	13875
@NP	2 h	13896
@NP	the enzyme substrate tetramethylbenzidine for 15 min	13905
@NP	the enzyme substrate tetramethylbenzidine	13905
@NP	15 min	13951
@NP	room temperature	13961
@NP	PBS	13979
@NP	the plates	14000
@NP	each step	14017
@NP	The enzyme reaction	14028
@NP	100 ml of 1 M phosphoric acid per well	14070
@NP	100 ml	14070
@NP	1 M phosphoric acid per well	14080
@NP	1 M phosphoric acid	14080
@NP	well	14104
@NP	the absorbance	14113
@NP	450 nm	14144
@NP	Sample values	14152
@NP	the standard curve in the linear range	14187
@NP	the standard curve	14187
@NP	the linear range	14209
@NP	The biological activity of the secreted GDNF	14227
@NP	The biological activity	14227
@NP	the secreted GDNF	14254
@NP	the	14254
@NP	GDNF	14267
@NP	a PC12 cell line	14289
@NP	GDNF receptor GFRa1 and Ret -LRB- Chen et al. , 2001 -RRB-	14330
@NP	GDNF receptor GFRa1	14330
@NP	Ret -LRB- Chen et al. , 2001 -RRB-	14354
@NP	Ret	14354
@NP	Chen	14359
@NP	et al. , 2001	14364
@NP	et al.	14364
@NP	2001	14372
@NP	Brie ¯ y , 2 3 104 PC12-GFRa-Ret cells	14379
@NP	Brie ¯ y	14379
@NP	2 3 104 PC12-GFRa-Ret cells	14387
@NP	2 3	14387
@NP	104 PC12-GFRa-Ret cells	14391
@NP	each well	14429
@NP	a 24-well plate -LRB- Costar -RRB- that had been coated with poly-L-lysine	14442
@NP	a 24-well plate	14442
@NP	Costar	14459
@NP	poly-L-lysine	14493
@NP	attachment	14514
@NP	the cells	14526
@NP	CM	14552
@NP	OECs or GDNF OECs	14560
@NP	PBS	14579
@NP	negative control	14595
@NP	100 ng/ml GDNF	14616
@NP	the positive control	14635
@NP	GDNF	14657
@NP	as previously described -LRB- Chen et al. , 2000 -RRB-	14675
@NP	as previously described	14675
@NP	as previously	14675
@NP	Chen	14700
@NP	et al. , 2000	14705
@NP	et al.	14705
@NP	2000	14713
@NP	Five days later	14720
@NP	the effect of GDNF on cell differentiation	14737
@NP	the effect	14737
@NP	GDNF on cell differentiation	14751
@NP	GDNF	14751
@NP	cell differentiation	14759
@NP	Cells	14796
@NP	one or more neurites of a length	14813
@NP	one or more neurites	14813
@NP	a length	14837
@NP	twice the diameter of the cell body	14856
@NP	twice the diameter	14856
@NP	the cell body	14878
@NP	Each value	14917
@NP	the mean ± SEM sampled from three independent experiments	14931
@NP	the mean ± SEM	14931
@NP	three independent experiments	14959
@NP	Hoechst labelling	14990
@NP	OECs When cells reached con ¯ uence , monolayers of purified OECs or GDNF OECs	15011
@NP	OECs	15011
@NP	cells	15021
@NP	¯ uence , monolayers of purified OECs or GDNF OECs	15038
@NP	¯ uence	15038
@NP	monolayers of purified OECs or GDNF OECs	15046
@NP	monolayers	15046
@NP	purified OECs or GDNF OECs	15060
@NP	37 °C	15105
@NP	1.5 µg/ml	15113
@NP	the nuclear ¯ uorochrome bisbenzimide -LRB- Hoechst 33342 ; Sigma -RRB-	15126
@NP	the nuclear ¯ uorochrome bisbenzimide	15126
@NP	Hoechst 33342 ; Sigma	15164
@NP	Hoechst 33342	15164
@NP	Sigma	15179
@NP	15 min	15190
@NP	several washes in Dulbecco 's modified Eagle medium -LRB- DMEM -RRB-	15204
@NP	several washes	15204
@NP	Dulbecco 's modified Eagle medium -LRB- DMEM -RRB-	15222
@NP	Dulbecco 's modified Eagle medium	15222
@NP	Dulbecco 's	15222
@NP	DMEM	15256
@NP	cells	15263
@NP	transplantation	15304
@NP	Surgical procedures Animal care and use	15321
@NP	Surgical procedures	15321
@NP	Animal care and use	15341
@NP	recommended NIH guidelines	15370
@NP	Female adult Sprague ± Dawley rats	15398
@NP	2 % pentobarbital sodium -LRB- 0.2 ml/kg -RRB-	15455
@NP	2 % pentobarbital sodium	15455
@NP	0.2 ml/kg	15480
@NP	Laminectomy	15510
@NP	the dorsal surface	15546
@NP	the T8 ± 9 segment , followed by a transection at T8 using microscissors	15568
@NP	the T8 ± 9 segment	15568
@NP	a transection at T8	15598
@NP	a transection	15598
@NP	T8	15615
@NP	microscissors	15624
@NP	The distal stump	15639
@NP	veri ® cation of complete transection	15690
@NP	veri ® cation	15690
@NP	complete transection	15705
@NP	Rats	15727
@NP	stereotaxic injections	15746
@NP	four sites	15774
@NP	the midline	15788
@NP	cord stumps	15808
@NP	ventral funiculus , grey commissure , dorsal CST , gracile fasciculus	15821
@NP	ventral funiculus	15821
@NP	grey commissure	15840
@NP	dorsal CST	15857
@NP	gracile fasciculus	15869
@NP	1 mm from the transaction site -LRB- Ramon-Cueto et al. , 1998 -RRB-	15892
@NP	1 mm	15892
@NP	the transaction site -LRB- Ramon-Cueto et al. , 1998 -RRB-	15902
@NP	the transaction site	15902
@NP	Ramon-Cueto	15924
@NP	et al. , 1998	15936
@NP	et al.	15936
@NP	1998	15944
@NP	sterile glass needles	15956
@NP	total	15982
@NP	41 animals	15989
@NP	eight animals	16019
@NP	a transection	16042
@NP	no grafted OECs	16061
@NP	each site	16082
@NP	0.5 µl DMEM	16101
@NP	15	16119
@NP	a graft	16131
@NP	normal OECs	16142
@NP	each site receiving 0.5 µl OEC suspension containing about 50 000 cells	16155
@NP	each site	16155
@NP	0.5 µl OEC suspension	16175
@NP	50 000 cells	16214
@NP	18	16238
@NP	a graft	16250
@NP	GDNF OECs	16261
@NP	each site receiving 0.5 µl cell suspension containing about 50 000 cells	16272
@NP	each site	16272
@NP	0.5 µl cell suspension	16292
@NP	50 000 cells	16332
@NP	rats	16363
@NP	22 ±	16381
@NP	25 °C	16384
@NP	highly absorbent bedding	16392
@NP	cefazolin sodium -LRB- 40 mg/day -RRB- for up to 1	16432
@NP	cefazolin sodium -LRB- 40 mg/day -RRB-	16432
@NP	cefazolin sodium	16432
@NP	40 mg/day	16450
@NP	up to 1	16465
@NP	week	16473
@NP	bladder expression	16492
@NP	normal function	16529
@NP	RT-PCR analysis	16555
@NP	Two months	16571
@NP	cell transplantation , animals of the OEC or GDNF OEC group	16588
@NP	cell transplantation	16588
@NP	animals of the OEC or GDNF OEC group	16610
@NP	animals	16610
@NP	the OEC or GDNF OEC group	16621
@NP	a lethal dose of pentobarbital sodium and T7 ± 9 spinal cord tissue	16668
@NP	a lethal dose of pentobarbital sodium	16668
@NP	a lethal dose	16668
@NP	pentobarbital sodium	16685
@NP	T7 ± 9 spinal cord tissue	16710
@NP	T7	16710
@NP	± 9 spinal cord tissue	16712
@NP	Total RNA	16749
@NP	the tissue using TRIzol -LRB- Gibco BRL -RRB-	16777
@NP	the tissue	16777
@NP	TRIzol -LRB- Gibco BRL -RRB-	16794
@NP	TRIzol	16794
@NP	Gibco BRL	16802
@NP	the RNA concentration	16817
@NP	RNA extraction	16875
@NP	the samples	16891
@NP	RNase-free DNase	16922
@NP	I	16939
@NP	cDNA	16946
@NP	a Dmniscript TM PT kit -LRB- Qiagen -RRB-	16973
@NP	a Dmniscript TM PT kit	16973
@NP	Qiagen	16997
@NP	PCR	17010
@NP	specific primers	17015
@NP	forward	17033
@NP	5 ` - AATATGCCCGAAGATTATCC-3 ` ; reverse , 5 ` - GTTTAGCGGAATGCTTTCTT-3 `	17042
@NP	5	17042
@NP	AATATGCCCGAAGATTATCC-3	17045
@NP	reverse , 5 ` - GTTTAGCGGAATGCTTTCTT-3 `	17070
@NP	reverse	17070
@NP	5	17079
@NP	GTTTAGCGGAATGCTTTCTT-3	17082
@NP	GDNF cDNA to yield 466 bp amplified products	17132
@NP	466 bp	17151
@NP	products	17168
@NP	the RT-PCR	17190
@NP	b-actin -LRB- primers : forward , 5-AAGATTTGGCACCACACTTTCTAC - 3 ` ;	17202
@NP	b-actin	17202
@NP	primers : forward , 5-AAGATTTGGCACCACACTTTCTAC - 3 `	17211
@NP	primers : forward , 5-AAGATTTGGCACCACACTTTCTAC -	17211
@NP	primers	17211
@NP	5-AAGATTTGGCACCACACTTTCTAC	17229
@NP	reverse	17261
@NP	5 ` - CACGGTTGGCCTTAGGGTT - 3 ` -RRB-	17270
@NP	5	17270
@NP	- CACGGTTGGCCTTAGGGTT - 3 `	17272
@NP	3	17294
@NP	GDNF	17320
@NP	Forty picomoles of each primer and 1 mg DNA	17326
@NP	Forty picomoles	17326
@NP	each primer and 1 mg DNA	17345
@NP	each primer	17345
@NP	1 mg DNA	17361
@NP	PCR	17384
@NP	a programmable heating block	17414
@NP	cycles	17449
@NP	denaturation	17470
@NP	95 °C	17486
@NP	1 min	17495
@NP	annealing	17513
@NP	55 °C for 1 min and DNA extension	17526
@NP	55 °C	17526
@NP	1 min and DNA extension	17535
@NP	1 min	17535
@NP	DNA extension	17545
@NP	72 °C for 1 min	17562
@NP	72 °C	17562
@NP	1 min	17571
@NP	30 cycles of PCR	17584
@NP	30 cycles	17584
@NP	PCR	17597
@NP	samples	17602
@NP	1.5 % agarose gel	17634
@NP	1.5 %	17634
@NP	agarose gel	17639
@NP	Gels	17652
@NP	ethidium bromide	17675
@NP	ultraviolet light	17715
@NP	Retrograde tracing with HRP Twelve animals	17734
@NP	Retrograde	17734
@NP	HRP Twelve animals	17758
@NP	three controls , four from the OEC and six from the GDNF OEC group	17778
@NP	three controls , four from the OEC	17778
@NP	three controls	17778
@NP	four from the OEC	17794
@NP	four	17794
@NP	the OEC	17804
@NP	six from the GDNF OEC group	17816
@NP	six	17816
@NP	the GDNF OEC group	17825
@NP	HRP retrograde	17859
@NP	Eight weeks	17883
@NP	surgery	17901
@NP	an aqueous suspension of 30 % HRP -LRB- Sigma ; RZ > 3.0 -RRB-	17910
@NP	an aqueous suspension	17910
@NP	30 % HRP -LRB- Sigma ; RZ > 3.0 -RRB-	17935
@NP	30 % HRP	17935
@NP	Sigma ; RZ > 3.0	17944
@NP	Sigma	17944
@NP	RZ > 3.0	17951
@NP	RZ >	17951
@NP	RZ	17951
@NP	3.0	17955
@NP	2 % dimethyl sulphoxide -LRB- Sigma -RRB-	17964
@NP	2 % dimethyl sulphoxide	17964
@NP	Sigma	17988
@NP	bilaterally three or four segments caudal to the transplant	18008
@NP	bilaterally three or four segments	18008
@NP	three or four	18020
@NP	the transplant	18053
@NP	diffusion of HRP	18077
@NP	diffusion	18077
@NP	HRP	18090
@NP	the transplant	18099
@NP	injection	18121
@NP	the surgical exposure	18132
@NP	the animals	18169
@NP	36 h	18201
@NP	1 % paraformaldehyde and 1.25 % glutaraldehyde	18240
@NP	1 % paraformaldehyde	18240
@NP	1.25 % glutaraldehyde	18264
@NP	The brain and spinal cord	18286
@NP	The brain	18286
@NP	spinal cord	18300
@NP	20 % sucrose in 0.1 M PBS at 4 °C overnight	18339
@NP	20 % sucrose	18339
@NP	0.1 M PBS at 4 °C overnight	18354
@NP	0.1 M PBS	18354
@NP	4 °C overnight	18367
@NP	4 °C	18367
@NP	the sensory motor cortex	18387
@NP	the forebrain and the magnocellular portion of the red nucleus in the midbrain	18415
@NP	the forebrain	18415
@NP	the magnocellular portion of the red nucleus in the midbrain	18433
@NP	the magnocellular portion	18433
@NP	the red nucleus in the midbrain	18462
@NP	the red nucleus	18462
@NP	the midbrain	18481
@NP	30 µm	18532
@NP	Every third section in the red nucleus or cortex	18539
@NP	Every third section	18539
@NP	the red nucleus or cortex	18562
@NP	tetramethylbenzidine -LRB- Sigma -RRB- and hydrogen peroxide	18619
@NP	tetramethylbenzidine -LRB- Sigma -RRB-	18619
@NP	tetramethylbenzidine	18619
@NP	Sigma	18641
@NP	hydrogen peroxide	18652
@NP	the method of Mesulam -LRB- Mesulam , 1978 -RRB-	18683
@NP	the method	18683
@NP	Mesulam -LRB- Mesulam , 1978 -RRB-	18697
@NP	Mesulam	18697
@NP	Mesulam	18706
@NP	1978	18715
@NP	neutral red	18749
@NP	the sections	18762
@NP	a light microscope	18795
@NP	The distal spinal cord including the transected area	18815
@NP	The distal spinal cord	18815
@NP	the transected area	18848
@NP	the injection	18907
@NP	con ® ned	18925
@NP	con ®	18925
@NP	there	18942
@NP	no spread of dye to the transplant	18952
@NP	no spread	18952
@NP	the transplant	18972
@NP	Animals that did not measure up to this criterion	18988
@NP	Animals	18988
@NP	this criterion	19023
@NP	the study	19059
@NP	identification of neurons in the red nucleus and cortex	19074
@NP	identification	19074
@NP	neurons in the red nucleus and cortex	19092
@NP	neurons	19092
@NP	the red nucleus and cortex	19103
@NP	the caudalmost section	19131
@NP	the nucleus magnocellularis and sensory motor cortex	19162
@NP	HRP-labelled neurons	19221
@NP	the first section for analysis	19278
@NP	the first section	19278
@NP	analysis	19300
@NP	The numbers	19310
@NP	HRPlabelled and neutral red-labelled rubrospinal neurons	19325
@NP	RSNs	19383
@NP	corticospinal neurons	19393
@NP	CSNs	19416
@NP	both sites	19425
@NP	a digitizing tablet and PC-based software -LRB- Metamorph -RRB-	19466
@NP	a digitizing tablet	19466
@NP	PC-based software -LRB- Metamorph -RRB-	19490
@NP	PC-based software	19490
@NP	Metamorph	19509
@NP	The criterion for a CSN	19521
@NP	The criterion	19521
@NP	a CSN	19539
@NP	an HRP-filled pyramidal shape >	19549
@NP	an HRP-filled pyramidal shape	19549
@NP	4 mm	19580
@NP	diameter	19588
@NP	the RSN	19602
@NP	only neurons with a clearly visible nucleus	19611
@NP	only neurons	19611
@NP	a clearly visible nucleus	19629
@NP	Antegrade	19669
@NP	dextran amine Antegrade tracing of CST fibres from the motor cortex	19705
@NP	dextran amine Antegrade	19705
@NP	CST fibres	19740
@NP	the motor cortex	19756
@NP	Ramon-Cueto et al. -LRB- 2000 -RRB-	19797
@NP	Ramon-Cueto et al.	19797
@NP	Ramon-Cueto	19797
@NP	et al.	19809
@NP	2000	19817
@NP	Brie ¯ y , animals	19824
@NP	Brie ¯ y	19824
@NP	animals	19832
@NP	anesthetized and two holes	19845
@NP	the cranium	19888
@NP	both sensorimotor cortices	19910
@NP	A 10 % solution	19938
@NP	dextran amine -LRB- BDA ; molecular weight 10 000 ; Molecular Probes -RRB-	19969
@NP	dextran amine	19969
@NP	BDA ; molecular weight 10 000 ; Molecular Probes	19984
@NP	BDA	19984
@NP	molecular weight 10 000 ; Molecular Probes	19989
@NP	molecular weight 10 000	19989
@NP	molecular weight	19989
@NP	10 000	20006
@NP	Molecular Probes	20014
@NP	eight sites of each sensorimotor cortex -LRB- 0.5 ml/site -RRB-	20060
@NP	eight sites	20060
@NP	each sensorimotor cortex -LRB- 0.5 ml/site -RRB-	20075
@NP	each sensorimotor cortex	20075
@NP	0.5 ml/site	20101
@NP	the entire hindlimb region	20123
@NP	Eighteen days	20151
@NP	rats	20172
@NP	spinal sections	20193
@NP	¯ uoresceinconjugated streptavidin	20229
@NP	BDA-containing corticospinal axons	20276
@NP	CST fibres	20324
@NP	we	20335
@NP	a method described previously -LRB- Blits et al. , 2000 -RRB-	20347
@NP	a method described previously	20347
@NP	a method	20347
@NP	Blits	20378
@NP	et al. , 2000	20384
@NP	et al.	20384
@NP	2000	20392
@NP	the number of CST fibres	20411
@NP	the number	20411
@NP	CST fibres	20425
@NP	the animals that survived for 8 weeks	20439
@NP	the animals	20439
@NP	8 weeks	20469
@NP	the centre of each lesion -LRB- between the proximal and distal scar -RRB-	20478
@NP	the centre	20478
@NP	each lesion -LRB- between the proximal and distal scar -RRB-	20492
@NP	each lesion	20492
@NP	the proximal and distal scar	20513
@NP	point 0	20592
@NP	this point	20606
@NP	fibre counting	20618
@NP	the sagittal sections and at 2.5 and 4.5 mm proximal and distal	20650
@NP	the sagittal sections	20650
@NP	at 2.5 and 4.5 mm proximal and distal	20676
@NP	at 2.5 and 4.5 mm	20676
@NP	the centre of the lesion	20717
@NP	the centre	20717
@NP	the lesion	20731
@NP	Immunohistochemistry Rats	20743
@NP	4 % paraformaldehyde in 0.1 M ice-cold phosphate buffer	20788
@NP	4 % paraformaldehyde	20788
@NP	0.1 M ice-cold phosphate buffer	20811
@NP	The spinal cord	20844
@NP	5 h	20887
@NP	30 % sucrose/PBS	20905
@NP	30 mm sagittal cryosections	20938
@NP	Hoechst-labelled OECs	20967
@NP	a ¯ uorescent microscope	21010
@NP	a 365 nm excitation filter and a 420 nm emission filter	21048
@NP	a 365 nm excitation filter	21048
@NP	a 420 nm emission filter	21079
@NP	immuno ¯ uorescence	21109
@NP	sections	21128
@NP	0.3 % Triton X-100 / 10 % normal goat serum in 0.1 M PBS	21173
@NP	0.3 % Triton X-100	21173
@NP	10 % normal goat serum in 0.1 M PBS	21191
@NP	10 %	21191
@NP	normal goat serum in 0.1 M PBS	21195
@NP	normal goat serum	21195
@NP	0.1 M PBS	21216
@NP	15 min	21230
@NP	Primary antibodies	21238
@NP	the sections overnight at 4 °C	21278
@NP	the sections overnight	21278
@NP	4 °C	21304
@NP	Each section	21309
@NP	mouse monoclonal immunoglobulin G	21347
@NP	neurofilaments -LRB- Sigma ; 1 : 200 -RRB- and anti-p75NGFR	21389
@NP	neurofilaments -LRB- Sigma ; 1 : 200 -RRB-	21389
@NP	neurofilaments	21389
@NP	Sigma ; 1 : 200	21405
@NP	Sigma	21405
@NP	1 : 200	21412
@NP	anti-p75NGFR	21425
@NP	The following day	21439
@NP	sections	21458
@NP	¯ uorescein	21487
@NP	goat anti-mouse and rhodamine-conjugated goat antirabbit -LRB- Promega -RRB-	21523
@NP	goat anti-mouse and rhodamine-conjugated goat antirabbit	21523
@NP	Promega	21581
@NP	secondary antibodies	21590
@NP	Slides	21612
@NP	Olympus ¯	21657
@NP	uorescent microscopy	21666
@NP	Neurofilament	21688
@NP	NF	21703
@NP	immunohistostaining	21707
@NP	3 mm wide strips of spinal tissue	21760
@NP	3 mm wide strips	21760
@NP	spinal tissue	21780
@NP	the lesion centre	21802
@NP	Slides	21821
@NP	an Olympus photo microscope -LRB- BX70 -RRB-	21862
@NP	an Olympus photo microscope	21862
@NP	BX70	21891
@NP	The photographs	21898
@NP	a video image analysis system -LRB- Metamorph -RRB- in conjunction	21934
@NP	a video image analysis system -LRB- Metamorph -RRB-	21934
@NP	a video image analysis system	21934
@NP	Metamorph	21965
@NP	conjunction	21979
@NP	a computer	21996
@NP	background correction	22014
@NP	the grey levels of each slide	22037
@NP	the grey levels	22037
@NP	each slide	22056
@NP	the mean of grey levels for all slides from each animal	22101
@NP	the mean	22101
@NP	grey levels for all slides from each animal	22113
@NP	grey levels	22113
@NP	all slides from each animal	22129
@NP	all slides	22129
@NP	each animal	22145
@NP	statistical analysis	22175
@NP	Functional recovery Functional tests	22211
@NP	operation and 2 h , 3 days and 1 , 2 , 3 , 4 , 5 , 6 , 7 and 8 weeks	22270
@NP	operation	22270
@NP	2 h	22284
@NP	3 days	22289
@NP	1 , 2 , 3 , 4 , 5 , 6 , 7 and 8 weeks	22300
@NP	1	22300
@NP	2	22303
@NP	3	22306
@NP	4	22309
@NP	5	22312
@NP	6	22315
@NP	7	22318
@NP	8 weeks	22324
@NP	operation	22338
@NP	Locomotor activity	22349
@NP	the open-field walking scoring system	22388
@NP	One animal at a time	22427
@NP	One animal	22427
@NP	a time	22441
@NP	a circular plastic tray -LRB- 90 cm diameter , 24 cm wall height -RRB- for 5 min	22482
@NP	a circular plastic tray -LRB- 90 cm diameter , 24 cm wall height -RRB-	22482
@NP	a circular plastic tray	22482
@NP	90 cm diameter , 24 cm wall height	22507
@NP	90 cm diameter	22507
@NP	24 cm wall height	22523
@NP	5 min	22546
@NP	Behavioural recovery	22553
@NP	the BBB -LRB- Basso , Beattie , Bresnahan -RRB- scale	22598
@NP	Basso	22607
@NP	Beattie	22614
@NP	Bresnahan	22623
@NP	Basso	22641
@NP	et al. , 1996	22647
@NP	et al.	22647
@NP	1996	22655
@NP	21 different criteria of the movement of the hind limb	22683
@NP	21 different criteria	22683
@NP	the movement of the hind limb	22708
@NP	the movement	22708
@NP	the hind limb	22724
@NP	complete paralysis	22743
@NP	mobility	22774
@NP	a second test for hind limb function	22787
@NP	a second test	22787
@NP	hind limb function	22805
@NP	animals	22825
@NP	an inclined plane test -LRB- Rivlin and Tator , 1977 -RRB-	22851
@NP	an inclined plane test	22851
@NP	Rivlin and Tator , 1977	22875
@NP	Rivlin	22875
@NP	Tator , 1977	22886
@NP	Tator	22886
@NP	1977	22893
@NP	The maximum angle	22900
@NP	the animal	22927
@NP	a stable position	22953
@NP	5 s on the inclined plane	22975
@NP	5 s	22975
@NP	the inclined plane	22982
@NP	each evaluation	23022
@NP	we	23039
@NP	the rats for perineal infection	23061
@NP	the rats	23061
@NP	perineal infection	23074
@NP	wounds in the hind limbs	23094
@NP	wounds	23094
@NP	the hind limbs	23104
@NP	tail and foot autophagia	23124
@NP	Results Fig. 1 Structure of double-copy retroviral vector pN2A-GDNF .	23151
@NP	Results Fig.	23151
@NP	1 Structure of double-copy retroviral vector pN2A-GDNF	23164
@NP	1 Structure	23164
@NP	double-copy retroviral vector pN2A-GDNF	23179
@NP	The original Moloney murine leukaemia virus-based retroviral vector pN2A	23220
@NP	The original Moloney murine leukaemia	23220
@NP	virus-based retroviral vector pN2A	23258
@NP	a GDNF gene in the U3 region of the 3 ` - LTR	23302
@NP	a GDNF gene in the U3 region of the 3 `	23302
@NP	a GDNF gene	23302
@NP	the U3 region of the 3 `	23317
@NP	the	23317
@NP	region	23324
@NP	the 3	23334
@NP	LTR	23342
@NP	` neo '	23347
@NP	a G418/neomycin resistant gene	23356
@NP	a G418/neomycin	23356
@NP	` Double copy '	23388
@NP	the infected cell the transduced gene could be duplicated	23420
@NP	the infected cell	23420
@NP	the transduced gene	23438
@NP	the 5 ` - LTR -LRB- asterisk -RRB-	23497
@NP	the 5	23497
@NP	- LTR	23503
@NP	asterisk	23509
@NP	Placement of the foreign gene outside the retroviral transcriptional unit	23520
@NP	Placement	23520
@NP	the foreign gene outside the retroviral transcriptional unit	23533
@NP	the foreign gene	23533
@NP	the retroviral transcriptional unit	23558
@NP	the negative effects of the retroviral transcriptional unit	23628
@NP	the negative effects	23628
@NP	the retroviral transcriptional unit	23652
@NP	the expression of the foreign gene -LRB- Hantzopoulos et al. , 1989 -RRB-	23709
@NP	the expression	23709
@NP	the foreign gene -LRB- Hantzopoulos et al. , 1989 -RRB-	23727
@NP	the foreign gene	23727
@NP	Hantzopoulos	23745
@NP	et al. , 1989	23758
@NP	et al.	23758
@NP	1989	23766
@NP	Fig. 2 Characterization of a GDNF-overexpressing OECs cell line .	23774
@NP	Fig.	23774
@NP	2 Characterization of a GDNF-overexpressing OECs cell line	23779
@NP	2 Characterization	23779
@NP	a GDNF-overexpressing OECs cell line	23801
@NP	-LRB- A -RRB- Phases of GDNF OECs in primary cultures .	23839
@NP	-LRB- A -RRB-	23839
@NP	Phases of GDNF OECs in primary cultures	23843
@NP	Phases	23843
@NP	GDNF OECs in primary cultures	23853
@NP	GDNF OECs	23853
@NP	primary cultures	23866
@NP	-LRB- B -RRB- GDNF OECs double-stained with S-100 and Hoechst .	23884
@NP	-LRB- B -RRB-	23884
@NP	GDNF OECs double-stained with S-100 and Hoechst	23888
@NP	GDNF OECs	23888
@NP	S-100 and Hoechst	23918
@NP	S-100	23918
@NP	Hoechst	23928
@NP	C , D -RRB- GDNF	23938
@NP	OECs	23949
@NP	p75NGFR	24007
@NP	GFAP	24039
@NP	A small number of GFAP-positive cells that did not express p75NGFR	24045
@NP	A small number	24045
@NP	GFAP-positive cells that did not express p75NGFR	24063
@NP	GFAP-positive cells	24063
@NP	p75NGFR	24104
@NP	astrocytes -LRB- arrow in C -RRB-	24126
@NP	astrocytes	24126
@NP	arrow in C	24138
@NP	arrow	24138
@NP	C	24147
@NP	GFAP expression	24151
@NP	astrocytes	24188
@NP	OECs	24207
@NP	Immunostaining for GDNF	24213
@NP	Immunostaining	24213
@NP	GDNF	24232
@NP	GDNF OECs -LRB- E -RRB-	24258
@NP	GDNF OECs	24258
@NP	E	24269
@NP	normal OECs -LRB- F -RRB-	24280
@NP	normal OECs	24280
@NP	F	24293
@NP	Scale	24297
@NP	100 µm	24309
@NP	This figure	24317
@NP	colour	24346
@NP	supplementary material	24356
@NP	Brain Online	24382
@NP	Fig.	24397
@NP	3 Detection of ex vivo GDNF secretion from normal OECs and GDNF OECs by ELISA	24402
@NP	3 Detection	24402
@NP	ex vivo GDNF secretion from normal OECs and GDNF OECs by ELISA	24417
@NP	ex vivo GDNF secretion from normal OECs	24417
@NP	ex vivo GDNF secretion	24417
@NP	normal OECs	24445
@NP	GDNF OECs by ELISA	24461
@NP	GDNF OECs	24461
@NP	ELISA	24474
@NP	-LRB- A -RRB- GDNF standard curve	24481
@NP	-LRB- A -RRB-	24481
@NP	GDNF standard curve	24485
@NP	the GDNF Emax ImmunoAssay System	24520
@NP	-LRB- B -RRB- Bar graph	24554
@NP	-LRB- B -RRB-	24554
@NP	Bar graph	24558
@NP	ex vivo GDNF secretion between normal OECs and GDNF OEC groups	24578
@NP	ex vivo GDNF secretion	24578
@NP	normal OECs and GDNF OEC groups	24609
@NP	GDNF production by control uninfected OECs	24642
@NP	GDNF production	24642
@NP	control uninfected OECs	24661
@NP	95 pg/ml per 106 cells	24689
@NP	95 pg/ml	24689
@NP	106 cells	24702
@NP	GDNF OECs	24721
@NP	an average of 25 ng GDNF/106 cells/24	24740
@NP	an average	24740
@NP	25 ng GDNF/106 cells/24	24754
@NP	P <	24782
@NP	P	24782
@NP	<	24784
@NP	0.01 versus normal OEC group .	24786
@NP	0.01	24786
@NP	normal OEC group .	24798
@NP	normal OEC	24798
@NP	Fig. 4 Bar graph comparing differentiation ratios of PC12-GFRa1	24817
@NP	Fig. 4 Bar graph	24817
@NP	differentiation ratios of PC12-GFRa1	24844
@NP	differentiation ratios	24844
@NP	PC12-GFRa1	24870
@NP	Ret cells among groups	24882
@NP	Ret cells	24882
@NP	groups	24898
@NP	PC12-GFRa1-Ret cells	24906
@NP	5 days	24946
@NP	DMEM	24958
@NP	control	24964
@NP	GDNF 50 ng/ml	24974
@NP	CM obtained from GDNF OECs or uninfected OECs	24989
@NP	CM	24989
@NP	GDNF OECs or uninfected OECs	25006
@NP	GDNF OECs	25006
@NP	uninfected OECs	25019
@NP	P <	25037
@NP	P	25037
@NP	<	25039
@NP	0.05	25041
@NP	control group	25053
@NP	ΔΔP < 0.01 versus OEC supernatant	25068
@NP	ΔΔP	25068
@NP	0.01	25074
@NP	OEC supernatant	25086
@NP	Fig. 5 Expression of GDNF mRNA transcripts	25104
@NP	Fig. 5 Expression	25104
@NP	GDNF mRNA transcripts	25125
@NP	8 weeks	25160
@NP	operation	25174
@NP	RT-PCR analysis	25187
@NP	Lane A , GDNF OEC group ; lane B , OEC group ; lane C , marker .	25204
@NP	Lane A , GDNF OEC group	25204
@NP	Lane A	25204
@NP	GDNF OEC group	25212
@NP	lane B , OEC group	25228
@NP	lane B	25228
@NP	OEC group	25236
@NP	lane C , marker	25247
@NP	lane C	25247
@NP	marker	25255
@NP	The upper GDNF band	25263
@NP	460 bp	25293
@NP	the control actin band	25304
@NP	100 bp	25337
@NP	rats injected with GDNF OECs	25348
@NP	rats	25348
@NP	GDNF OECs	25367
@NP	expression of GDNF mRNA in the spinal cord	25378
@NP	expression	25378
@NP	GDNF mRNA in the spinal cord	25392
@NP	GDNF mRNA	25392
@NP	the spinal cord	25405
@NP	Fig. 6 Transgenetic gene expression of OEC implants in vivo .	25450
@NP	Fig.	25450
@NP	6 Transgenetic gene expression of OEC implants in vivo	25455
@NP	6 Transgenetic gene expression	25455
@NP	OEC implants in vivo	25489
@NP	OEC implants	25489
@NP	vivo	25505
@NP	The OECs	25511
@NP	the recombinant retrovirus containing GFP	25539
@NP	the recombinant retrovirus	25539
@NP	GFP	25577
@NP	the lesion of the spinal cord	25598
@NP	the lesion	25598
@NP	the spinal cord	25612
@NP	-LRB- A -RRB- The lesion gap	25629
@NP	-LRB- A -RRB-	25629
@NP	The lesion gap	25633
@NP	an intensively GFAP-positive -LRB- red -RRB- border of reactive astrocytes	25665
@NP	an intensively GFAP-positive -LRB- red -RRB- border	25665
@NP	reactive astrocytes	25710
@NP	-LRB- B -RRB- Persistent expression of GFP -LRB- green -RRB-	25731
@NP	-LRB- B -RRB- Persistent expression of GFP	25731
@NP	-LRB- B -RRB- Persistent expression	25731
@NP	B	25732
@NP	GFP	25760
@NP	OECs	25784
@NP	at least 2 months	25795
@NP	implantation	25819
@NP	determined by native GFP ¯ uorescence	25836
@NP	native GFP ¯	25850
@NP	Inset	25874
@NP	the magnified image	25886
@NP	Most GFP-positive OECs	25911
@NP	p75 NGFR -LRB- blue -RRB-	25957
@NP	p75 NGFR	25957
@NP	blue	25967
@NP	Additional p75NGFR staining outside the confines of GFP labelling	25974
@NP	Additional p75NGFR staining	25974
@NP	the confines of GFP labelling	26010
@NP	the confines	26010
@NP	GFP labelling	26026
@NP	the Schwann cells	26056
@NP	the spinal cord	26092
@NP	Ruitenberg	26125
@NP	et al.	26136
@NP	2002	26144
@NP	Scale	26151
@NP	150 µm	26163
@NP	This figure	26171
@NP	colour	26200
@NP	supplementary material	26210
@NP	Brain Online	26236
@NP	Fig. 7 NF immunostaining through the spinal cord lesion 8 weeks after injury .	26251
@NP	Fig. 7 NF immunostaining	26251
@NP	the spinal cord lesion 8 weeks	26284
@NP	the spinal cord lesion	26284
@NP	8 weeks	26307
@NP	injury	26321
@NP	-LRB- A -RRB- Haematoxylin and eosin staining	26329
@NP	-LRB- A -RRB-	26329
@NP	Haematoxylin and eosin staining	26333
@NP	spinal cord transection	26383
@NP	an obvious traverse scar	26419
@NP	the T8 lesion epicentres -LRB- arrow -RRB-	26447
@NP	the T8	26447
@NP	lesion epicentres -LRB- arrow -RRB-	26454
@NP	lesion epicentres	26454
@NP	arrow	26473
@NP	neuronal necrosis , reactive gliosis and cavitation	26484
@NP	neuronal necrosis	26484
@NP	reactive gliosis	26503
@NP	cavitation	26524
@NP	adjacent rostral and caudal regions	26538
@NP	-LRB- B -RRB- GFAP immunochemistry	26575
@NP	-LRB- B -RRB-	26575
@NP	GFAP immunochemistry	26579
@NP	glial scar -LRB- arrow -RRB- in spinal cord lesion	26606
@NP	glial scar -LRB- arrow -RRB-	26606
@NP	glial scar	26606
@NP	arrow	26618
@NP	spinal cord lesion	26628
@NP	C , D	26649
@NP	C	26649
@NP	D	26652
@NP	control animals , NF immuno	26658
@NP	control animals	26658
@NP	NF immuno	26675
@NP	¯ uorescence at the lesion site -LRB- outlined in C -RRB-	26684
@NP	¯ uorescence	26684
@NP	the lesion site -LRB- outlined in C -RRB-	26699
@NP	the lesion site	26699
@NP	C	26728
@NP	mostly scattered profiles , and many NFimmunoreactive fibres	26741
@NP	mostly scattered profiles	26741
@NP	many NFimmunoreactive fibres	26772
@NP	the host ± scar interface -LRB- arrows -RRB-	26817
@NP	the host ± scar interface	26817
@NP	arrows	26842
@NP	E , F	26852
@NP	E	26852
@NP	F	26855
@NP	the normal OEC group	26861
@NP	NF-positive axons -LRB- arrows -RRB-	26893
@NP	NF-positive axons	26893
@NP	arrows	26912
@NP	the lesion -LRB- outlined in E -RRB-	26944
@NP	the lesion	26944
@NP	E	26968
@NP	G , H	26973
@NP	G	26973
@NP	H	26976
@NP	the GDNF OEC group	26982
@NP	a dramatically increased amount of NFpositive fibres -LRB- arrows -RRB-	27002
@NP	a dramatically increased amount	27002
@NP	NFpositive fibres -LRB- arrows -RRB-	27037
@NP	NFpositive fibres	27037
@NP	arrows	27056
@NP	the lesion site -LRB- outlined in G -RRB- ; some of them	27077
@NP	the lesion site -LRB- outlined in G -RRB-	27077
@NP	the lesion site	27077
@NP	G	27106
@NP	some of them	27110
@NP	some	27110
@NP	them	27118
@NP	the invaded dorsal root -LRB- asterisk -RRB-	27141
@NP	the invaded dorsal root	27141
@NP	asterisk	27166
@NP	The axonal profiles within the centre of the lesion site	27177
@NP	The axonal profiles	27177
@NP	the centre of the lesion site	27204
@NP	the centre	27204
@NP	the lesion site	27218
@NP	a variety of orientations	27238
@NP	a variety	27238
@NP	orientations	27251
@NP	Scale bars = 100 µm in A , C , E , G ; 25 µm in B , D , F , H.	27265
@NP	Scale bars	27265
@NP	= 100 µm in A , C , E , G ; 25 µm in B , D , F , H.	27276
@NP	= 100 µm in A , C , E , G	27276
@NP	= 100 µm	27276
@NP	100	27278
@NP	A , C , E , G	27288
@NP	25 µm in B , D , F , H.	27300
@NP	25 µm	27300
@NP	B , D , F , H.	27309
@NP	B	27309
@NP	D	27312
@NP	F	27315
@NP	H.	27318
@NP	This figure	27321
@NP	colour	27350
@NP	supplementary material	27360
@NP	Brain Online	27386
@NP	Fig. 8 High-magnification microscope images of NF-positive axons	27401
@NP	Fig.	27401
@NP	8 High-magnification microscope images of NF-positive axons	27406
@NP	8 High-magnification microscope images	27406
@NP	NF-positive axons	27448
@NP	the lesion centre	27484
@NP	-LRB- A -RRB- Normal OEC group .	27503
@NP	-LRB- A -RRB-	27503
@NP	Normal OEC group	27507
@NP	-LRB- B -RRB- GDNF OEC group .	27525
@NP	-LRB- B -RRB-	27525
@NP	GDNF OEC group	27529
@NP	OECs	27555
@NP	Hoechst -LRB- blue -RRB- / p75NGFR -LRB- red -RRB- labelling	27577
@NP	Hoechst -LRB- blue -RRB-	27577
@NP	Hoechst	27577
@NP	p75NGFR -LRB- red -RRB-	27592
@NP	p75NGFR	27592
@NP	red	27601
@NP	numerous NF-positive axons -LRB- green -RRB-	27622
@NP	numerous NF-positive axons	27622
@NP	the injury site 8 weeks after injury	27673
@NP	the injury site	27673
@NP	8 weeks	27689
@NP	injury	27703
@NP	close association with implanted OECs or GDNF OECs	27720
@NP	close association	27720
@NP	implanted OECs or GDNF OECs	27743
@NP	arrows	27772
@NP	the GDNF OEC group	27784
@NP	NF-positive axons	27804
@NP	bundles -LRB- arrowhead -RRB-	27842
@NP	bundles	27842
@NP	arrowhead	27851
@NP	Scale	27863
@NP	20 µm	27875
@NP	The bar graph	27882
@NP	grey levels of NF activity in the lesion in the different groups 8 weeks	27902
@NP	grey levels	27902
@NP	NF activity in the lesion in the different groups 8 weeks	27917
@NP	NF activity	27917
@NP	the lesion in the different groups 8 weeks	27932
@NP	the lesion	27932
@NP	the different groups	27946
@NP	8 weeks	27967
@NP	surgery	27981
@NP	NF immunoactivities	27990
@NP	animals	28041
@NP	GDNF OECs	28059
@NP	those receiving normal OECs -LRB- P < 0.01 -RRB-	28077
@NP	those	28077
@NP	normal OECs -LRB- P < 0.01 -RRB-	28093
@NP	normal OECs	28093
@NP	P < 0.01	28106
@NP	P	28106
@NP	< 0.01	28108
@NP	<	28108
@NP	0.01	28110
@NP	animals receiving OECs	28146
@NP	animals	28146
@NP	OECs	28164
@NP	those receiving DMEM	28177
@NP	those	28177
@NP	DMEM	28193
@NP	P <	28201
@NP	P	28201
@NP	<	28203
@NP	0.01	28205
@NP	DMEM group	28217
@NP	ΔΔP < 0.01 versus OEC group	28229
@NP	ΔΔP	28229
@NP	0.01	28235
@NP	OEC group	28247
@NP	ANOVA test	28258
@NP	least significant difference test , n = 5	28281
@NP	least significant difference test	28281
@NP	n = 5	28316
@NP	n	28316
@NP	5	28320
@NP	This figure	28323
@NP	colour	28352
@NP	supplementary material	28362
@NP	Brain Online	28388
@NP	Fig. 9 Photomicrographs	28403
@NP	HRP	28435
@NP	CSN -LRB- A , C , E , G -RRB- and RSN -LRB- B , D , F , H -RRB- 8 weeks	28461
@NP	CSN -LRB- A , C , E , G -RRB-	28461
@NP	CSN	28461
@NP	A	28466
@NP	C	28469
@NP	E , G	28472
@NP	RSN -LRB- B , D , F , H -RRB-	28481
@NP	RSN	28481
@NP	B	28486
@NP	D , F , H	28489
@NP	8 weeks	28498
@NP	thoracic transection	28512
@NP	The dark purple-staining cells	28534
@NP	-LRB- A , B -RRB-	28583
@NP	A , B	28584
@NP	A	28584
@NP	B	28587
@NP	animal	28604
@NP	-LRB- C , D -RRB-	28612
@NP	group	28624
@NP	-LRB- E , F -RRB-	28631
@NP	E , F	28632
@NP	E	28632
@NP	F	28635
@NP	group	28642
@NP	-LRB- G , H -RRB- GDNF OEC group .	28649
@NP	G , H -RRB- GDNF	28650
@NP	group	28665
@NP	the DMEM group -LRB- control -RRB-	28675
@NP	the DMEM group	28675
@NP	control	28691
@NP	few HRP-labelled neurons	28701
@NP	the CSN or RSN	28743
@NP	animals	28762
@NP	OECs	28780
@NP	a few labelled cells	28791
@NP	Numerous HRP-labelled neurons	28827
@NP	the GDNF OEC group	28871
@NP	Scale	28891
@NP	200 µm	28903
@NP	This figure	28911
@NP	colour	28940
@NP	supplementary material	28950
@NP	Brain Online	28976
@NP	Fig. 10 Bar graph	28991
@NP	the numbers of HRP-labelled RSN and CSN among animal groups 8 weeks	29017
@NP	the numbers of HRP-labelled RSN	29017
@NP	the numbers	29017
@NP	HRP-labelled RSN	29032
@NP	CSN among animal groups 8 weeks	29053
@NP	CSN	29053
@NP	animal groups 8 weeks	29063
@NP	animal groups	29063
@NP	8 weeks	29077
@NP	surgery	29091
@NP	animals	29103
@NP	GDNF OECs	29121
@NP	there	29132
@NP	significantly more RSN	29143
@NP	CSN labelled than in those receiving normal OECs -LRB- P < 0.01 -RRB-	29170
@NP	CSN	29170
@NP	those receiving normal OECs -LRB- P < 0.01 -RRB-	29191
@NP	those	29191
@NP	normal OECs -LRB- P < 0.01 -RRB-	29207
@NP	normal OECs	29207
@NP	P < 0.01	29220
@NP	P	29220
@NP	< 0.01	29222
@NP	<	29222
@NP	0.01	29224
@NP	More RSN and CSN	29231
@NP	More RSN	29231
@NP	CSN	29244
@NP	animals receiving OECs than in those receiving DMEM -LRB- P < 0.01 -RRB-	29265
@NP	animals	29265
@NP	OECs	29283
@NP	those receiving DMEM -LRB- P < 0.01 -RRB-	29296
@NP	those	29296
@NP	DMEM -LRB- P < 0.01 -RRB-	29312
@NP	DMEM	29312
@NP	P < 0.01	29318
@NP	P	29318
@NP	< 0.01	29320
@NP	<	29320
@NP	0.01	29322
@NP	P <	29331
@NP	P	29331
@NP	<	29333
@NP	0.01	29335
@NP	DMEM group	29347
@NP	ΔΔP < 0.01 versus OEC group	29359
@NP	ΔΔP	29359
@NP	0.01	29365
@NP	OEC group	29377
@NP	ANOVA test	29388
@NP	the least significant difference test , n =	29411
@NP	the least significant difference test	29411
@NP	n =	29450
@NP	3 ± 5	29454
@NP	Fig.	29460
@NP	11 BDA-traced corticospinal axons in the lesion 8 weeks after implantation	29465
@NP	11 BDA-traced corticospinal axons	29465
@NP	the lesion 8 weeks after implantation	29502
@NP	the lesion	29502
@NP	8 weeks	29513
@NP	implantation	29527
@NP	-LRB- A -RRB- Diagram of a sagittal spinal cord section	29541
@NP	-LRB- A -RRB-	29541
@NP	a sagittal spinal cord section	29556
@NP	the rostral part of the injury region	29598
@NP	the rostral part	29598
@NP	the injury region	29618
@NP	The locations of the images shown in C , F and I	29637
@NP	The locations	29637
@NP	the images shown in C , F and I	29654
@NP	the images	29654
@NP	C , F and I	29674
@NP	C	29674
@NP	F	29677
@NP	I	29683
@NP	box	29702
@NP	R = rostral ; V = ventral .	29708
@NP	R = rostral	29708
@NP	V = ventral	29721
@NP	V	29721
@NP	-LRB- B -RRB- Diagram of a sagittal spinal cord section	29734
@NP	-LRB- B -RRB-	29734
@NP	a sagittal spinal cord section	29749
@NP	the caudal part of the injury region	29791
@NP	the caudal part	29791
@NP	the injury region	29810
@NP	The locations of the images shown in E , H and K	29829
@NP	The locations	29829
@NP	the images shown in E , H and K	29846
@NP	the images	29846
@NP	E , H and K	29866
@NP	box	29894
@NP	C = caudal .	29900
@NP	C	29900
@NP	= caudal	29902
@NP	E	29919
@NP	the control group	29925
@NP	the transected CST	29944
@NP	little regeneration response	29970
@NP	the rostral end	30002
@NP	Few fibres	30019
@NP	the lesion	30057
@NP	the segment	30081
@NP	the lesion centre	30103
@NP	F , G , H	30123
@NP	the OEC group	30135
@NP	a few CST fibres	30150
@NP	termination bulbs and some fibres	30193
@NP	termination bulbs	30193
@NP	some fibres	30215
@NP	the lesion	30245
@NP	the segment	30268
@NP	the lesion centre	30290
@NP	I	30310
@NP	J , K	30313
@NP	the GDNF OEC group	30322
@NP	very robust fibre growth and termination bulb formation	30342
@NP	very robust fibre growth	30342
@NP	termination bulb formation	30371
@NP	many BDA-labelled axons	30417
@NP	the caudal end of the lesion	30454
@NP	the caudal end	30454
@NP	the lesion	30472
@NP	Scale bar = 50 µm in C , F , I ; 100 µm in D , G , J ; 150 µm in E , H , K.	30484
@NP	Scale bar	30484
@NP	= 50 µm in C , F , I ; 100 µm in D , G , J ; 150 µm in E , H ,	30494
@NP	= 50 µm	30494
@NP	50	30496
@NP	C , F , I ; 100 µm in D , G , J ; 150 µm in E , H ,	30505
@NP	C	30505
@NP	F , I ; 100 µm in D , G , J ; 150 µm in E , H ,	30508
@NP	F , I	30508
@NP	F	30508
@NP	I	30511
@NP	100 µm in D , G , J	30514
@NP	100 µm	30514
@NP	D , G , J	30524
@NP	150 µm in E , H ,	30533
@NP	150 µm	30533
@NP	E , H ,	30543
@NP	E	30543
@NP	H	30546
@NP	K.	30549
@NP	This figure	30552
@NP	colour	30581
@NP	supplementary material	30591
@NP	Brain Online	30617
@NP	Fig. 12 Quantitative comparison of CST regrowth	30632
@NP	Fig. 12 Quantitative comparison	30632
@NP	Fig. 12	30632
@NP	CST regrowth	30667
@NP	grey matter of the transected spinal cord 8 weeks	30694
@NP	grey matter	30694
@NP	the transected spinal cord 8 weeks	30709
@NP	the transected spinal cord	30709
@NP	8 weeks	30736
@NP	implantation	30750
@NP	variations	30782
@NP	efficiency	30811
@NP	the cortical BDA injections	30825
@NP	the fibre number	30854
@NP	4.5 mm	30879
@NP	the centre of the lesion	30900
@NP	the centre	30900
@NP	the lesion	30914
@NP	100 %	30936
@NP	all data	30945
@NP	relative percentages	30973
@NP	the control group	30998
@NP	few CST fibres	31017
@NP	the distal spinal cord	31049
@NP	the normal OEC group	31076
@NP	a few CST fibres	31098
@NP	the lesion	31133
@NP	the segment	31156
@NP	the lesion centre	31178
@NP	the GDNF OEC group	31200
@NP	more CST regrowth	31229
@NP	more CST	31229
@NP	regrowth	31238
@NP	the segment near the injury side	31260
@NP	the segment	31260
@NP	the injury side	31277
@NP	P <	31295
@NP	P	31295
@NP	<	31297
@NP	0.05	31299
@NP	P < 0.01 versus DMEM group ; ΔP < 0.05 , ΔΔP < 0.01 versus OEC group	31307
@NP	P <	31307
@NP	P	31307
@NP	0.01 versus DMEM group	31311
@NP	0.01	31311
@NP	; ΔP < 0.05 , ΔΔP < 0.01 versus OEC group	31333
@NP	ΔP < 0.05	31335
@NP	ΔP <	31335
@NP	ΔP	31335
@NP	0.05	31340
@NP	ΔΔP < 0.01 versus OEC group	31346
@NP	ΔΔP	31346
@NP	0.01	31352
@NP	OEC group	31364
@NP	ANOVA test	31375
@NP	least significant difference test , n = 5	31398
@NP	least significant difference test	31398
@NP	n = 5	31433
@NP	n	31433
@NP	5	31437
@NP	Fig.	31441
@NP	13 Functional analysis	31446
@NP	hindlimb movements following SCI among animal groups	31472
@NP	hindlimb movements	31472
@NP	SCI among animal groups	31501
@NP	SCI	31501
@NP	animal groups	31511
@NP	the BBB behavioural assessment -LRB- top -RRB-	31532
@NP	the BBB behavioural assessment	31532
@NP	top	31564
@NP	the inclined plane -LRB- IP -RRB- test -LRB- bottom -RRB-	31573
@NP	the inclined plane -LRB- IP -RRB- test	31573
@NP	IP	31593
@NP	bottom	31603
@NP	P <	31612
@NP	P	31612
@NP	<	31614
@NP	P	31624
@NP	< 0.01 versus control group ; ΔP <	31626
@NP	<	31626
@NP	0.01 versus control group ; ΔP <	31628
@NP	0.01 versus control group	31628
@NP	0.01	31628
@NP	control group	31640
@NP	ΔP <	31655
@NP	ΔP	31655
@NP	<	31658
@NP	0.05	31660
@NP	ΔΔP < 0.01 versus OEC group	31666
@NP	ΔΔP	31666
@NP	0.01	31672
@NP	OEC group	31684
@NP	ANOVA test	31695
@NP	least significant difference test , n =	31718
@NP	least significant difference test	31718
@NP	n =	31753
@NP	8 ± 18	31757
@NP	Characterization of GDNF OECs	31764
@NP	Characterization	31764
@NP	GDNF OECs	31784
@NP	The GDNF	31794
@NP	OECs	31803
@NP	primary cultures	31811
@NP	a spindlelike morphology with two or three processes or a ¯	31839
@NP	a spindlelike morphology with two	31839
@NP	a spindlelike morphology	31839
@NP	two	31869
@NP	three processes or a ¯	31876
@NP	three processes	31876
@NP	a ¯	31895
@NP	appearance	31901
@NP	Franceschini and Barnett	31913
@NP	1996 ; Li et al. , 1998 ; Gudino-Cabrera et al. , 2000 ; Wewetzer et al.	31939
@NP	1996	31939
@NP	Li et al. , 1998 ; Gudino-Cabrera et al. , 2000 ; Wewetzer et al.	31945
@NP	Li	31945
@NP	et al. , 1998 ; Gudino-Cabrera et al. , 2000 ; Wewetzer et al.	31948
@NP	et al. , 1998	31948
@NP	et al.	31948
@NP	1998	31956
@NP	Gudino-Cabrera et al. , 2000	31962
@NP	Gudino-Cabrera	31962
@NP	et al. , 2000	31977
@NP	et al.	31977
@NP	2000	31985
@NP	Wewetzer et al.	31991
@NP	Wewetzer	31991
@NP	et al.	32000
@NP	2002	32008
@NP	S-100 immunoreactivity	32025
@NP	Fig. 2A and B	32049
@NP	Fig. 2A	32049
@NP	B	32061
@NP	Immuno ¯ uorescent staining	32065
@NP	Immuno ¯	32065
@NP	the purity of GDNF OECs	32109
@NP	the purity	32109
@NP	GDNF OECs	32123
@NP	more than 92 %	32137
@NP	insertion of a new gene using a viral vector-mediated gene transfer	32178
@NP	insertion	32178
@NP	a new gene using a viral vector-mediated gene transfer	32191
@NP	a new gene	32191
@NP	a viral vector-mediated gene transfer	32208
@NP	normal cell functioning	32269
@NP	GDNF OEC cultures	32294
@NP	the expression of general cell markers	32345
@NP	the expression	32345
@NP	general cell markers	32363
@NP	the low-affinity neurotrophin receptor p75NGFR	32385
@NP	the Schwann cell marker S-100	32433
@NP	GFAP	32468
@NP	Fig. 2C and D	32486
@NP	GDNF OECs	32501
@NP	intensive immunostaining for p75 NGFR and weak immunostaining for GFAP	32540
@NP	intensive immunostaining for p75 NGFR	32540
@NP	intensive immunostaining	32540
@NP	p75 NGFR	32569
@NP	weak immunostaining for GFAP	32582
@NP	weak immunostaining	32582
@NP	GFAP	32606
@NP	A small amount of GFAP-positive cells that did not express p75NGFR	32612
@NP	A small amount	32612
@NP	GFAP-positive cells that did not express p75NGFR	32630
@NP	GFAP-positive cells	32630
@NP	p75NGFR	32671
@NP	astrocytes	32693
@NP	GFAP expression in astrocytes	32708
@NP	GFAP expression	32708
@NP	astrocytes	32727
@NP	that in OECs	32761
@NP	that	32761
@NP	OECs	32769
@NP	immunostain - ing for GDNF	32788
@NP	immunostain	32788
@NP	ing for GDNF	32801
@NP	ing	32801
@NP	GDNF	32809
@NP	GDNF OECs	32835
@NP	normal OECs	32853
@NP	Fig. 2E and F	32866
@NP	Fig. 2E	32866
@NP	F	32878
@NP	Ex vivo GDNF secretion	32882
@NP	biological effect The amount of GDNF secreted by GDNF OECs	32909
@NP	biological effect	32909
@NP	The amount of GDNF	32927
@NP	The amount	32927
@NP	GDNF	32941
@NP	GDNF OECs	32958
@NP	ELISA	32986
@NP	detection sensitivity	32997
@NP	31.2 pg / ml of GDNF	33022
@NP	31.2 pg	33022
@NP	ml of GDNF	33031
@NP	ml	33031
@NP	GDNF	33037
@NP	GDNF production by uninfected OECs	33043
@NP	GDNF production	33043
@NP	uninfected OECs	33062
@NP	95 pg/ml per 106 cells	33099
@NP	95 pg/ml	33099
@NP	106 cells	33112
@NP	GDNF OECs	33131
@NP	an average of 25 ng GDNF/106 cells/day -LRB- Fig. 3 -RRB-	33150
@NP	an average	33150
@NP	25 ng GDNF/106 cells/day -LRB- Fig. 3 -RRB-	33164
@NP	25 ng GDNF/106 cells/day	33164
@NP	Fig. 3	33190
@NP	The biological activity of the secreted GDNF	33199
@NP	The biological activity	33199
@NP	the secreted GDNF	33226
@NP	the	33226
@NP	GDNF	33239
@NP	PC12-GFRa-Ret cells	33263
@NP	72 h of culture	33290
@NP	72 h	33290
@NP	culture	33298
@NP	CM from normal OECs	33309
@NP	CM	33309
@NP	normal OECs	33317
@NP	5.4 6 1.87 % of cells	33330
@NP	5.4 6 1.87 %	33330
@NP	5.4 6	33330
@NP	1.87 %	33336
@NP	cells	33345
@NP	CM from GDNF OECs	33379
@NP	CM	33379
@NP	GDNF OECs	33387
@NP	cell differentiation	33398
@NP	that of normal OECs -LRB- Fig. 4 -RRB-	33445
@NP	that	33445
@NP	normal OECs -LRB- Fig. 4 -RRB-	33453
@NP	normal OECs	33453
@NP	Fig. 4	33466
@NP	This bioassay	33475
@NP	GDNF secreted from GDNF OECs	33504
@NP	GDNF	33504
@NP	GDNF OECs	33523
@NP	PC12 - GFRa-Ret cell differentiation	33582
@NP	PC12	33582
@NP	GFRa-Ret cell differentiation	33588
@NP	Transgenetic gene expression of OECs in vivo Eight weeks	33619
@NP	Transgenetic gene expression	33619
@NP	OECs in vivo Eight weeks	33651
@NP	OECs	33651
@NP	vivo	33659
@NP	Eight weeks	33664
@NP	surgery	33682
@NP	RT-PCR	33691
@NP	the mRNA level of GDNF	33718
@NP	the mRNA level	33718
@NP	GDNF	33736
@NP	the injured spinal cord -LRB- Fig. 5 -RRB-	33744
@NP	the injured spinal cord	33744
@NP	Fig. 5	33769
@NP	injured spinal cord injected with GDNF OECs	33781
@NP	injured spinal cord	33781
@NP	GDNF OECs	33815
@NP	significantly higher levels of GDNF mRNA expression	33826
@NP	significantly higher levels	33826
@NP	GDNF mRNA expression	33857
@NP	that in the spinal cord of rats injected with normal OECs	33906
@NP	that	33906
@NP	the spinal cord of rats injected with normal OECs	33914
@NP	the spinal cord	33914
@NP	rats injected with normal OECs	33933
@NP	rats	33933
@NP	normal OECs	33952
@NP	This result	33965
@NP	ex vivo transduction of OECs with retrovectors	33995
@NP	ex vivo transduction	33995
@NP	OECs with retrovectors	34019
@NP	OECs	34019
@NP	retrovectors	34029
@NP	increased GDNF expression in vivo , up to at least 2 months after implantation	34067
@NP	increased GDNF expression	34067
@NP	vivo	34096
@NP	at least 2 months after implantation	34108
@NP	at least 2 months	34108
@NP	implantation	34132
@NP	the expression of the transgene and the location of OECs in the lesion	34165
@NP	the expression of the transgene	34165
@NP	the expression	34165
@NP	the transgene	34183
@NP	the location of OECs in the lesion	34201
@NP	the location	34201
@NP	OECs in the lesion	34217
@NP	OECs	34217
@NP	the lesion	34225
@NP	OECs	34237
@NP	the recombinant retrovirus	34261
@NP	green ¯ uorescent protein -LRB- GFP -RRB-	34299
@NP	green ¯ uorescent protein	34299
@NP	GFP	34325
@NP	the lesion of spinal cord	34349
@NP	the lesion	34349
@NP	spinal cord	34363
@NP	Fig. 6 , 2 months	34388
@NP	Fig. 6	34388
@NP	2 months	34396
@NP	implantation	34411
@NP	GFP-labelled OECs	34425
@NP	a dense mass	34462
@NP	elongated , brightly ¯ uorescent cells extending from the lesion site	34478
@NP	¯ uorescent cells extending from the lesion site	34498
@NP	¯ uorescent cells	34498
@NP	the lesion site	34530
@NP	Most GFPpositive implants	34547
@NP	p75NGFR	34597
@NP	These results	34606
@NP	the implanted OECs	34635
@NP	the injured spinal cord for at least 2 months	34683
@NP	the injured spinal cord	34683
@NP	at least 2 months	34711
@NP	implantation	34735
@NP	The OECs	34749
@NP	the lesion gap	34775
@NP	an intensively GFAPpositive border of reactive astrocytes	34815
@NP	an intensively GFAPpositive border	34815
@NP	reactive astrocytes	34853
@NP	We	34874
@NP	OECs across the astrocytic barrier	34892
@NP	OECs	34892
@NP	the astrocytic barrier	34904
@NP	the spinal cord	34932
@NP	These results	34949
@NP	good agreement with previous report	34970
@NP	good agreement	34970
@NP	previous report	34990
@NP	Ruitenberg and colleagues -LRB- Ruitenberg et al. , 2002 -RRB-	35009
@NP	Ruitenberg and colleagues	35009
@NP	Ruitenberg	35036
@NP	et al. , 2002	35047
@NP	et al.	35047
@NP	2002	35055
@NP	Axonal regeneration Spinal cord transection lesion	35062
@NP	an obvious traverse scar at the T8 lesion epicentres	35134
@NP	an obvious traverse scar	35134
@NP	the T8 lesion epicentres	35162
@NP	neuronal necrosis , reactive gliosis and cavitation	35191
@NP	neuronal necrosis	35191
@NP	reactive gliosis	35210
@NP	cavitation	35231
@NP	adjacent rostral and caudal regions -LRB- Fig. 7A and B -RRB-	35245
@NP	adjacent rostral and caudal regions	35245
@NP	Fig. 7A and B	35282
@NP	Fig. 7A	35282
@NP	B	35294
@NP	control animals	35301
@NP	2 months	35318
@NP	lesion	35333
@NP	only scattered NF-positive fibres	35340
@NP	the central scar	35388
@NP	many NF-immunoreactive fibres	35409
@NP	the host ± scar interface -LRB- Fig. 7C and D -RRB-	35455
@NP	the host ± scar interface	35455
@NP	Fig. 7C and D	35480
@NP	Fig. 7C	35480
@NP	D	35492
@NP	Fig. 7E and F	35508
@NP	Fig. 7E	35508
@NP	F	35520
@NP	NF-positive axons	35533
@NP	the lesion in normal OEC group	35574
@NP	the lesion	35574
@NP	normal OEC group	35588
@NP	increased amounts of NF-positive fibres	35619
@NP	increased amounts	35619
@NP	NF-positive fibres	35640
@NP	the lesion site in the GDNF OEC group	35673
@NP	the lesion site	35673
@NP	the GDNF OEC group	35692
@NP	some of them	35716
@NP	some	35716
@NP	them	35724
@NP	the invaded dorsal root -LRB- Fig. 7G and H -RRB-	35747
@NP	the invaded dorsal root	35747
@NP	Fig. 7G and H	35772
@NP	Fig. 7G	35772
@NP	H	35784
@NP	Highmagni fication microscopy	35788
@NP	numerous NF-positive axons	35825
@NP	the lesion	35868
@NP	close association with implanted OECs or GDNF OECs -LRB- Fig. 8 -RRB-	35889
@NP	close association	35889
@NP	implanted OECs or GDNF OECs	35912
@NP	Fig. 8	35941
@NP	the GDNF OEC group	35953
@NP	NF-positive axons	35973
@NP	bundles	36011
@NP	Statistical analysis	36020
@NP	significantly higher grey levels of NF immunoactivity	36050
@NP	significantly higher grey levels	36050
@NP	NF immunoactivity	36086
@NP	animals receiving GDNF OECs than in those receiving normal OECs	36107
@NP	animals	36107
@NP	GDNF OECs	36125
@NP	those receiving normal OECs	36143
@NP	those	36143
@NP	normal OECs	36159
@NP	Figure 9 shows RSN and CSN	36172
@NP	Figure 9 shows	36172
@NP	RSN and CSN	36187
@NP	injections of HRP	36215
@NP	injections	36215
@NP	HRP	36229
@NP	the low thoracic and upper lumbar region	36238
@NP	the low thoracic	36238
@NP	upper lumbar region	36259
@NP	HRP retrograde staining	36280
@NP	most labelled RSN	36316
@NP	most	36316
@NP	RSN	36330
@NP	the ventral ± lateral portion	36350
@NP	the magnocellular nucleus of the red nucleus -LRB- Fig. 9B , D , F , H -RRB-	36381
@NP	the magnocellular nucleus	36381
@NP	the red nucleus -LRB- Fig. 9B , D , F , H -RRB-	36410
@NP	the red nucleus	36410
@NP	Fig. 9B	36427
@NP	D , F , H	36436
@NP	Neurons in the cortex -LRB- Fig. 9A , C , E , G -RRB-	36446
@NP	Neurons	36446
@NP	the cortex -LRB- Fig. 9A , C , E , G -RRB-	36457
@NP	the cortex	36457
@NP	Fig. 9A	36469
@NP	C , E , G	36478
@NP	the RSN	36508
@NP	Fig. 10	36529
@NP	the number of HRP-labelled RSN and CSN	36538
@NP	the number	36538
@NP	HRP-labelled RSN and CSN	36552
@NP	HRP-labelled RSN	36552
@NP	CSN	36573
@NP	all groups of animals	36593
@NP	all groups	36593
@NP	animals	36607
@NP	average	36619
@NP	normal animals	36631
@NP	~ 386 and ~ 2737 neurons	36647
@NP	~ 386	36647
@NP	~ 2737 neurons	36656
@NP	both sides of the RSN and CSN	36687
@NP	both sides	36687
@NP	the RSN and CSN	36701
@NP	thoracic transection	36738
@NP	few HRP-labelled RSN or CSN	36760
@NP	few HRP-labelled RSN	36760
@NP	CSN	36784
@NP	the DMEM group	36805
@NP	treatment of normal OECs	36826
@NP	treatment	36826
@NP	normal OECs	36839
@NP	a few cells -LRB- RSN , 50 ; CSN , 355 -RRB- labelled with HRP	36852
@NP	a few cells -LRB- RSN , 50 ; CSN , 355 -RRB-	36852
@NP	a few cells	36852
@NP	RSN , 50 ; CSN , 355	36865
@NP	RSN	36865
@NP	50 ; CSN	36870
@NP	50	36870
@NP	CSN	36874
@NP	355	36879
@NP	HRP	36898
@NP	OEC transplantation	36917
@NP	a permissive environment	36955
@NP	a small percentage	36993
@NP	neurons	37026
@NP	the caudal spinal cord -LRB- P < 0.01 versus DMEM group -RRB-	37053
@NP	the caudal spinal cord	37053
@NP	P	37077
@NP	0.01	37081
@NP	DMEM group	37093
@NP	The highest regeneration ratio	37106
@NP	the GDNF OEC group	37144
@NP	approximately 97 in RSN and 776 in CSN	37164
@NP	approximately 97 in RSN	37164
@NP	approximately 97	37164
@NP	RSN	37184
@NP	776 in CSN	37192
@NP	776	37192
@NP	CSN	37199
@NP	HRP	37222
@NP	These numbers	37228
@NP	signifi - cantly higher	37247
@NP	signifi	37247
@NP	those in the normal OEC group -LRB- P < 0.01 -RRB-	37275
@NP	those	37275
@NP	the normal OEC group -LRB- P < 0.01 -RRB-	37284
@NP	the normal OEC group	37284
@NP	P < 0.01	37306
@NP	P	37306
@NP	< 0.01	37308
@NP	<	37308
@NP	0.01	37310
@NP	the axonal regeneration	37336
@NP	antegrade tracing experiments	37361
@NP	antegrade	37361
@NP	experiments	37379
@NP	Figure 11	37407
@NP	the images for BDA-traced corticospinal axons 8 weeks	37423
@NP	the images	37423
@NP	BDA-traced corticospinal axons 8 weeks	37438
@NP	BDA-traced corticospinal axons	37438
@NP	8 weeks	37469
@NP	spinal cord injury	37483
@NP	the control group	37506
@NP	the transected CST	37525
@NP	little regeneration response	37551
@NP	the segment rostral	37583
@NP	the lesion centre	37606
@NP	the normal OEC group	37637
@NP	a few CST fibres	37658
@NP	termination bulbs	37701
@NP	some fibres	37723
@NP	the lesion	37753
@NP	the segment	37776
@NP	the lesion centre	37798
@NP	Quantitative analysis	37817
@NP	more BDA-traced CST fibres	37853
@NP	the segment near the injury side in the GDNF OEC group	37894
@NP	the segment	37894
@NP	the injury side in the GDNF OEC group	37911
@NP	the injury side	37911
@NP	the GDNF OEC group	37930
@NP	a distal segment 4.5 mm away from the lesion centre	37968
@NP	a distal segment	37968
@NP	4.5 mm	37985
@NP	the lesion centre	38002
@NP	no significant differences	38021
@NP	the OEC and GDNF OEC groups -LRB- Fig. 12 -RRB-	38067
@NP	the OEC	38067
@NP	GDNF OEC groups -LRB- Fig. 12 -RRB-	38079
@NP	GDNF OEC groups	38079
@NP	Fig. 12	38096
@NP	Behavioural assessment Figure 13	38106
@NP	Behavioural assessment Figure	38106
@NP	13	38136
@NP	the behavioural results	38145
@NP	the 8-week assessment period for each group of animals	38176
@NP	the 8-week assessment period	38176
@NP	each group of animals	38209
@NP	each group	38209
@NP	animals	38223
@NP	All injured rats	38232
@NP	complete hind limb paralysis	38260
@NP	injury	38307
@NP	The BBB scores	38315
@NP	the range of 0 ±	38338
@NP	the range	38338
@NP	0 ±	38351
@NP	2 in the control animals	38353
@NP	2	38353
@NP	the control animals	38358
@NP	transplantation of the OECs	38389
@NP	transplantation	38389
@NP	the OECs	38408
@NP	hind limb functional recovery	38418
@NP	hind limb	38418
@NP	functional recovery	38428
@NP	8 weeks	38469
@NP	transplantation	38483
@NP	all 15 animals	38500
@NP	that achieved by any of the eight	38549
@NP	that	38549
@NP	any of the eight	38566
@NP	any	38566
@NP	the eight	38573
@NP	P < 0.01	38593
@NP	P	38593
@NP	< 0.01	38595
@NP	<	38595
@NP	0.01	38597
@NP	Five of the 15 experimental animals from the OEC group	38604
@NP	Five	38604
@NP	the 15 experimental animals from the OEC group	38612
@NP	the 15 experimental animals	38612
@NP	the OEC group	38645
@NP	their body weight	38673
@NP	their hind limbs	38694
@NP	the other 10 animals	38712
@NP	ankle , knee and hip movements in one or both legs	38737
@NP	ankle , knee and hip movements	38737
@NP	one or both legs	38770
@NP	one	38770
@NP	both legs	38777
@NP	weight	38814
@NP	The GDNF OEC group	38822
@NP	more functional recovery	38850
@NP	the normal OEC group	38880
@NP	8 weeks	38901
@NP	transplantation	38915
@NP	P < 0.01	38932
@NP	P	38932
@NP	< 0.01	38934
@NP	<	38934
@NP	0.01	38936
@NP	10 of the 18 rats treated with GDNF OECs	38943
@NP	10	38943
@NP	the 18 rats treated with GDNF OECs	38949
@NP	the 18 rats	38949
@NP	GDNF OECs	38974
@NP	a coordinated manner	38998
@NP	Differences in score on the inclined plane test among the three groups	39020
@NP	Differences	39020
@NP	score on the inclined plane test among the three groups	39035
@NP	score	39035
@NP	the inclined plane test among the three groups	39044
@NP	the inclined plane test	39044
@NP	the three groups	39074
@NP	2 weeks after operation	39119
@NP	2 weeks	39119
@NP	operation	39133
@NP	rats in the OEC group	39144
@NP	rats	39144
@NP	the OEC group	39152
@NP	more functional recovery	39180
@NP	those in the control group -LRB- P < 0.05 -RRB-	39210
@NP	those	39210
@NP	the control group -LRB- P < 0.05 -RRB-	39219
@NP	the control group	39219
@NP	P < 0.05	39238
@NP	P	39238
@NP	< 0.05	39240
@NP	<	39240
@NP	0.05	39242
@NP	5 weeks	39255
@NP	implantation animals in the GDNF OEC group	39269
@NP	implantation animals	39269
@NP	the GDNF OEC group	39293
@NP	a higher score than those in the OEC group -LRB- P < 0.05 -RRB-	39316
@NP	a higher score	39316
@NP	those in the OEC group -LRB- P < 0.05 -RRB-	39336
@NP	those	39336
@NP	the OEC group -LRB- P < 0.05 -RRB-	39345
@NP	the OEC group	39345
@NP	P < 0.05	39360
@NP	P	39360
@NP	< 0.05	39362
@NP	<	39362
@NP	0.05	39364
@NP	Discussion Combining transplantation and gene therapy	39372
@NP	Discussion Combining transplantation	39372
@NP	gene therapy	39413
@NP	one of the most powerful strategies	39437
@NP	one	39437
@NP	the most powerful strategies	39444
@NP	CNS repair	39484
@NP	implantation of OECs in the injured spinal cord	39499
@NP	implantation	39499
@NP	OECs in the injured spinal cord	39515
@NP	OECs	39515
@NP	the injured spinal cord	39523
@NP	long-distance regeneration and func	39576
@NP	tional recovery	39613
@NP	SCI -LRB- Li et al. , 1997 ; Ramon-Cueto et al. , 2000 -RRB-	39639
@NP	SCI	39639
@NP	Li	39644
@NP	et al. , 1997 ; Ramon-Cueto et al. , 2000	39647
@NP	et al.	39647
@NP	1997 ; Ramon-Cueto et al.	39655
@NP	1997	39655
@NP	Ramon-Cueto et al.	39661
@NP	Ramon-Cueto	39661
@NP	et al.	39673
@NP	2000	39681
@NP	there	39688
@NP	much interest	39697
@NP	OECs	39724
@NP	the regenerative properties of these cells	39740
@NP	the regenerative properties	39740
@NP	these cells	39771
@NP	researchers	39794
@NP	OECs	39830
@NP	¯ uorescent markers	39846
@NP	experiments -LRB- Ruitenberg et al. , 2002 -RRB-	39877
@NP	experiments	39877
@NP	Ruitenberg	39890
@NP	et al. , 2002	39901
@NP	et al.	39901
@NP	2002	39909
@NP	transgenic animals	39925
@NP	a xenogeneic protein	39955
@NP	a source for modified OECs -LRB- Imaizumi et al. , 2000 -RRB-	39979
@NP	a source	39979
@NP	modified OECs -LRB- Imaizumi et al. , 2000 -RRB-	39992
@NP	modified OECs	39992
@NP	Imaizumi	40007
@NP	et al. , 2000	40016
@NP	et al.	40016
@NP	2000	40024
@NP	the present study	40034
@NP	OECs	40053
@NP	exogenous neurotrophic factor	40099
@NP	the transected spinal cord	40156
@NP	Ex vivo gene therapy	40184
@NP	Ex vivo gene	40184
@NP	therapy	40197
@NP	a valuable approach	40208
@NP	the achievement	40231
@NP	long-term and site-specific delivery of therapeutic agents in the CNS	40250
@NP	long-term and site-specific delivery	40250
@NP	therapeutic agents in the CNS	40290
@NP	therapeutic agents	40290
@NP	the CNS	40312
@NP	Both retroviral and adenovirus vectors	40321
@NP	gene transfer	40386
@NP	Retrovectors	40401
@NP	high efficiency	40429
@NP	no viral genes	40457
@NP	they	40475
@NP	long-term expression	40492
@NP	host cellular immune responses -LRB- Robbins et al. , 1998 -RRB-	40523
@NP	host cellular immune responses	40523
@NP	host	40523
@NP	Robbins et al. , 1998	40555
@NP	Robbins	40555
@NP	et al.	40563
@NP	1998	40571
@NP	the present study	40581
@NP	high levels of transgenic GDNF mRNA	40600
@NP	high levels	40600
@NP	transgenic GDNF mRNA	40615
@NP	even 2 months	40654
@NP	implantation	40674
@NP	the GFP OECs	40696
@NP	the	40724
@NP	genetically modified OECs	40739
@NP	the foreign gene in the spinal cord lesion	40806
@NP	the foreign gene	40806
@NP	the spinal cord lesion	40826
@NP	The sustained high-level expression of GDNF in OEC implants	40850
@NP	The sustained high-level expression	40850
@NP	GDNF in OEC implants	40889
@NP	GDNF	40889
@NP	OEC implants	40897
@NP	the possibility	40917
@NP	the growth-promoting properties of OECs and the microenvironment	40949
@NP	the growth-promoting properties	40949
@NP	OECs and the microenvironment	40984
@NP	OECs	40984
@NP	the microenvironment	40993
@NP	the lesion site	41017
@NP	the acute	41049
@NP	the chronic phase following injury	41075
@NP	the chronic phase	41075
@NP	injury	41103
@NP	Retrovectors	41111
@NP	the viral LTR sequence	41139
@NP	the expression of various gene cassettes	41188
@NP	the expression	41188
@NP	various gene cassettes	41206
@NP	No changes in morphology and expression of general cell marker proteins	41230
@NP	No changes	41230
@NP	morphology and expression of general cell marker proteins	41244
@NP	morphology and expression	41244
@NP	general cell marker proteins	41273
@NP	transduction of OECs	41322
@NP	transduction	41322
@NP	OECs	41338
@NP	retroviral vectors in this study	41346
@NP	retroviral vectors	41346
@NP	this study	41368
@NP	ex vivo gene transfer	41390
@NP	implants of transduced OECs into the site of a spinal cord lesion	41413
@NP	implants	41413
@NP	OECs	41436
@NP	the site of a spinal cord lesion	41446
@NP	the site	41446
@NP	a spinal cord lesion	41458
@NP	typical bipolar morphology	41515
@NP	gene transfer with retroviral pN2A-GDNF vectors	41559
@NP	gene transfer	41559
@NP	retroviral pN2A-GDNF vectors	41578
@NP	normal cell functioning	41630
@NP	GDNF	41655
@NP	a potent trophic factor	41689
@NP	midbrain dopaminergic neurons	41717
@NP	Lin et al. , 1993 ; Beck et al. , 1995 ; Tomac et al. , 1995	41748
@NP	Lin	41748
@NP	et al. , 1993 ; Beck et al. , 1995 ; Tomac et al. , 1995	41752
@NP	et al. , 1993	41752
@NP	et al.	41752
@NP	1993	41760
@NP	Beck et al. , 1995	41766
@NP	Beck	41766
@NP	et al. , 1995	41771
@NP	et al.	41771
@NP	1995	41779
@NP	Tomac et al. , 1995	41785
@NP	Tomac	41785
@NP	et al. , 1995	41791
@NP	et al.	41791
@NP	1995	41799
@NP	It	41806
@NP	GDNF	41837
@NP	the survival of motoneurons both in vitro	41865
@NP	the survival	41865
@NP	motoneurons	41881
@NP	vivo	41914
@NP	Henderson	41920
@NP	et al. , 1994	41930
@NP	et al.	41930
@NP	1994	41938
@NP	Li et al. , 1995	41944
@NP	Li	41944
@NP	et al. , 1995	41947
@NP	et al.	41947
@NP	1995	41955
@NP	Oppenheim et al. , 1995	41961
@NP	Oppenheim	41961
@NP	et al. , 1995	41971
@NP	et al.	41971
@NP	1995	41979
@NP	Yan et al. , 1995	41985
@NP	Yan	41985
@NP	et al. , 1995	41989
@NP	et al.	41989
@NP	1995	41997
@NP	Houenou et al. , 1996	42003
@NP	Houenou	42003
@NP	et al. , 1996	42011
@NP	et al.	42011
@NP	1996	42019
@NP	the spinal cord	42044
@NP	GDNF	42061
@NP	a trophic effect	42073
@NP	corticospinal neurons	42093
@NP	their long-term survival	42128
@NP	axotomy -LRB- Giehl et al. , 1997 -RRB-	42159
@NP	axotomy	42159
@NP	Giehl	42168
@NP	et al. , 1997	42174
@NP	et al.	42174
@NP	1997	42182
@NP	the present study	42192
@NP	we	42211
@NP	treatment with OECs with a modified GDNF gene	42231
@NP	treatment	42231
@NP	OECs with a modified GDNF gene	42246
@NP	OECs	42246
@NP	a modified GDNF gene	42256
@NP	an increase	42293
@NP	the regeneration of corticospinal or rubrospinal axons in adult rats	42308
@NP	the regeneration	42308
@NP	corticospinal or rubrospinal axons in adult rats	42328
@NP	corticospinal or rubrospinal axons	42328
@NP	adult rats	42366
@NP	spinal cord transection compared with treatment with normal OECs	42383
@NP	spinal cord transection	42383
@NP	treatment with normal OECs	42421
@NP	treatment	42421
@NP	normal OECs	42436
@NP	The HRP retrograde labelling studies	42449
@NP	injured axons	42512
@NP	the transection site	42557
@NP	Numerous HRP-labelled neurons	42579
@NP	8 weeks	42623
@NP	SCI in the GDNF OEC group	42637
@NP	SCI	42637
@NP	the GDNF OEC group	42644
@NP	the normal OEC group	42676
@NP	less than half of the HRP-labelled neurons	42698
@NP	less than half	42698
@NP	the HRP-labelled neurons	42716
@NP	BDA antegrade tracing experiments	42756
@NP	BDA antegrade	42756
@NP	experiments	42778
@NP	more CST fibres	42805
@NP	the lesion	42839
@NP	the segment	42862
@NP	the lesion centre in the GDNF OEC group	42884
@NP	the lesion centre	42884
@NP	the GDNF OEC group	42905
@NP	the normal OEC group	42932
@NP	NF immunochemical labelling	42954
@NP	large number of fibres	42994
@NP	large number	42994
@NP	fibres	43010
@NP	the lesioned spinal cord following GDNF OEC injections	43020
@NP	the lesioned spinal cord	43020
@NP	GDNF OEC injections	43055
@NP	These results	43076
@NP	GDNF ex vivo gene delivery	43103
@NP	GDNF	43103
@NP	ex vivo gene delivery	43108
@NP	the growth-promoting properties of OECs	43144
@NP	the growth-promoting properties	43144
@NP	OECs	43179
@NP	SCI	43190
@NP	There	43195
@NP	several possible explanations for this phenomenon	43205
@NP	several possible explanations	43205
@NP	this phenomenon	43239
@NP	GDNF	43263
@NP	a chemotropic effect	43276
@NP	the growth of axons	43308
@NP	the growth	43308
@NP	axons	43322
@NP	regions with the highest concentration of growth factor	43331
@NP	regions	43331
@NP	the highest concentration of growth factor	43344
@NP	the highest concentration	43344
@NP	growth factor	43373
@NP	GDNF	43398
@NP	the survival ratio of RSN and CSN	43416
@NP	the survival ratio	43416
@NP	RSN and CSN	43438
@NP	axotomy	43456
@NP	an increased number of regenerated corticospinal or rubrospinal fibres	43482
@NP	an increased number	43482
@NP	regenerated corticospinal or rubrospinal fibres	43505
@NP	recent studies	43564
@NP	OECs	43609
@NP	GDNF receptor GFRa1 -LRB- Woodhall et al. , 2001 -RRB-	43622
@NP	GDNF receptor GFRa1	43622
@NP	Woodhall	43643
@NP	et al. , 2001	43652
@NP	et al.	43652
@NP	2001	43660
@NP	high levels of GDNF secreted from GDNF OECs	43678
@NP	high levels	43678
@NP	GDNF secreted from GDNF OECs	43693
@NP	GDNF	43693
@NP	GDNF OECs	43712
@NP	trophic effects on themselves	43731
@NP	trophic effects	43731
@NP	themselves	43750
@NP	The locomotor functions of animals	43762
@NP	The locomotor functions	43762
@NP	animals	43789
@NP	the inclined plane method of Rivlin and BBB scale	43818
@NP	plane method of Rivlin and BBB	43831
@NP	plane method	43831
@NP	Rivlin and BBB	43847
@NP	The BBB scoring system	43869
@NP	other locomotor scoring systems in several respects	43905
@NP	other locomotor scoring systems	43905
@NP	several respects	43940
@NP	the score	43965
@NP	a summation of component behaviours	43982
@NP	a summation	43982
@NP	component behaviours	43997
@NP	Each BBB score	44019
@NP	fulfilment of a unique set of criteria	44043
@NP	fulfilment	44043
@NP	a unique set of criteria	44057
@NP	a unique set	44057
@NP	criteria	44073
@NP	the scores	44093
@NP	many behavioural traits	44114
@NP	a detailed characterization of rat locomotor function	44152
@NP	a detailed characterization	44152
@NP	rat locomotor function	44183
@NP	the scores	44216
@NP	observations of rat recovery	44240
@NP	observations	44240
@NP	rat recovery	44256
@NP	SCI	44274
@NP	The ordering of the scores	44279
@NP	The ordering	44279
@NP	the scores	44295
@NP	progressive recovery	44314
@NP	each recovery stage	44344
@NP	better locomotion	44375
@NP	the preceding stage -LRB- Basso et al. , 1996 -RRB-	44398
@NP	the preceding stage	44398
@NP	Basso	44419
@NP	et al. , 1996	44425
@NP	et al.	44425
@NP	1996	44433
@NP	the BBB scale and the inclined plane method	44446
@NP	the BBB scale	44446
@NP	the inclined plane method	44464
@NP	we	44491
@NP	a progressive recovery	44507
@NP	time	44535
@NP	three groups	44546
@NP	The functional recovery in the GDNF OEC group	44560
@NP	The functional recovery	44560
@NP	the GDNF OEC group	44587
@NP	statistically signi ®	44613
@NP	cant improvements	44633
@NP	the normal OEC group	44665
@NP	This result	44687
@NP	accordance with the morphological experiments	44705
@NP	accordance	44705
@NP	the morphological experiments	44721
@NP	Significant improvements of locomotor function	44752
@NP	Significant improvements	44752
@NP	locomotor function	44780
@NP	the GDNF OEC and normal OEC groups	44821
@NP	the GDNF OEC	44821
@NP	normal OEC groups	44838
@NP	the control group	44870
@NP	The enhanced recovery of function in the GDNF OEC group	44889
@NP	The enhanced recovery	44889
@NP	function in the GDNF OEC group	44914
@NP	function	44914
@NP	the GDNF OEC group	44926
@NP	the enhanced outgrowth of a still very limited number of nerve fibres	44977
@NP	the enhanced outgrowth	44977
@NP	a still very limited number of nerve fibres	45003
@NP	a still very limited number	45003
@NP	nerve fibres	45034
@NP	our retrograde	45061
@NP	results	45098
@NP	spinal cord transection	45113
@NP	rats from the control group	45138
@NP	rats	45138
@NP	the control group	45148
@NP	severe tissue loss	45177
@NP	the transection centre	45204
@NP	A positive correlation	45228
@NP	the increased tissue sparing with higher locomotor scores after SCI	45254
@NP	the increased tissue	45254
@NP	higher locomotor scores	45288
@NP	SCI	45318
@NP	Basso et al. , 1996	45352
@NP	Basso	45352
@NP	et al.	45358
@NP	1996	45366
@NP	It	45373
@NP	the transplanted OECs	45396
@NP	a beneficial effect on tissue sparing	45423
@NP	a beneficial effect	45423
@NP	tissue sparing	45446
@NP	other investigators	45474
@NP	recent publications -LRB- Takami et al. , 2002 ; Plant et al. , 2003 -RRB-	45497
@NP	recent publications	45497
@NP	Takami	45518
@NP	et al. , 2002 ; Plant et al. , 2003	45525
@NP	et al.	45525
@NP	2002 ; Plant et al.	45533
@NP	2002	45533
@NP	Plant et al.	45539
@NP	Plant	45539
@NP	et al.	45545
@NP	2003	45553
@NP	GDNF secreted by the OEC	45570
@NP	GDNF	45570
@NP	the OEC	45587
@NP	the tissue loss	45615
@NP	the GDNF administration	45635
@NP	tissue sparing	45684
@NP	a contusion model -LRB- Cheng et al. , 2002 -RRB-	45702
@NP	a contusion model	45702
@NP	Cheng	45721
@NP	et al. , 2002	45727
@NP	et al.	45727
@NP	2002	45735
@NP	GDNF secreted by the OEC	45755
@NP	GDNF	45755
@NP	the OEC	45772
@NP	the repair or survival	45800
@NP	spinal motor neurons	45826
@NP	the functional recovery -LRB- Watabe et al. , 2000 ; Cheng et al. , 2002 -RRB-	45878
@NP	the functional recovery	45878
@NP	Watabe	45903
@NP	et al. , 2000 ; Cheng et al. , 2002	45910
@NP	et al.	45910
@NP	2000 ; Cheng et al.	45918
@NP	2000	45918
@NP	Cheng et al.	45924
@NP	Cheng	45924
@NP	et al.	45930
@NP	2002	45938
@NP	summary	45948
@NP	the present study	45957
@NP	the growthpromoting properties of OECs	45986
@NP	the growthpromoting properties	45986
@NP	OECs	46020
@NP	these cells	46058
@NP	an increased level of GDNF	46107
@NP	an increased level	46107
@NP	GDNF	46129
@NP	Genetic engineering of OECs	46135
@NP	Genetic engineering	46135
@NP	OECs	46158
@NP	new possibilities for future clinical applications in SCI	46172
@NP	new possibilities	46172
@NP	future clinical applications in SCI	46194
@NP	future clinical applications	46194
@NP	SCI	46226
@NP	Note added in proof	46232
@NP	Note	46232
@NP	proof	46246
@NP	this manuscript	46255
@NP	revision Ruitenberg	46281
@NP	et al.	46301
@NP	2003	46309
@NP	their paper	46325
@NP	the point of the effect of genetically modified OECs on tissue sparing	46353
@NP	the point	46353
@NP	the effect of genetically modified OECs on tissue sparing	46366
@NP	the effect	46366
@NP	genetically modified OECs on tissue sparing	46380
@NP	genetically modified OECs	46380
@NP	tissue sparing	46409
@NP	Their results	46425
@NP	the notion	46459
@NP	the behavioural effect observed in the present study	46475
@NP	the behavioural effect	46475
@NP	the present study	46510
@NP	this way	46557
@NP	Acknowledgements	46568
@NP	We	46585
@NP	Professor Xuan Bao for her helpful suggestions and valuable comments	46594
@NP	Professor Xuan Bao	46594
@NP	her helpful suggestions and valuable comments	46617
@NP	her helpful suggestions	46617
@NP	valuable comments	46645
@VP	has emerged as a very promising therapy for spinal cord repair	648
@VP	emerged as a very promising therapy for spinal cord repair	652
@VP	linederived neurotrophic factor -LRB- GDNF -RRB- to promote spinal cord repair	815
@VP	to promote spinal cord repair	854
@VP	promote spinal cord repair	857
@VP	was transduced into OECs using a retroviral-based system	899
@VP	transduced into OECs using a retroviral-based system	903
@VP	using a retroviral-based system	924
@VP	to express and secrete biologically active GDNF in vitro	1019
@VP	express and secrete biologically active GDNF in vitro	1022
@VP	express	1022
@VP	secrete biologically active GDNF in vitro	1034
@VP	were examined	1203
@VP	examined	1208
@VP	were assessed	1253
@VP	assessed	1258
@VP	was evaluated at the morphological level	1289
@VP	evaluated at the morphological level	1293
@VP	to significantly improve recovery after spinal cord injury -LRB- SCI -RRB-	1451
@VP	significantly improve recovery after spinal cord injury -LRB- SCI -RRB-	1454
@VP	overexpressed neurotrophic factors	1629
@VP	opens new avenues for the treatment of SCI	1668
@VP	Revised October 23 , 2003 Accepted October 24 , 2003	2381
@VP	is one of the most devastating forms of trauma experienced by humans	2519
@VP	experienced by humans	2566
@VP	to treat SCI	2793
@VP	treat SCI	2796
@VP	regrow and reconnect	3659
@VP	is still insufficient -LRB- Gudino-Cabrera et al. , 2000 -RRB-	3680
@VP	have been well documented -LRB- Tuszynski , 1999 ; Jones et al. , 2001 -RRB-	3962
@VP	been well documented -LRB- Tuszynski , 1999 ; Jones et al. , 2001 -RRB-	3967
@VP	documented -LRB- Tuszynski , 1999 ; Jones et al. , 2001 -RRB-	3977
@VP	are known	4070
@VP	known	4074
@VP	was reported to promote rubrospinal tract -LRB- RST -RRB- regeneration	4497
@VP	reported to promote rubrospinal tract -LRB- RST -RRB- regeneration	4501
@VP	to promote rubrospinal tract -LRB- RST -RRB- regeneration	4510
@VP	promote rubrospinal tract -LRB- RST -RRB- regeneration	4513
@VP	has limited effects on corticospinal tract -LRB- CST -RRB-	4563
@VP	been found to augment the growth of corticospinal axons after spinal cord injury	4698
@VP	found to augment the growth of corticospinal axons after spinal cord injury	4703
@VP	to augment the growth of corticospinal axons after spinal cord injury	4709
@VP	augment the growth of corticospinal axons after spinal cord injury	4712
@VP	promote the death of some corticospinal neurons -LRB- Giehl et al. , 2001 -RRB-	4799
@VP	blocking TrkC activity	4923
@VP	expressing GDNF	5392
@VP	cultured cortical neurons -LRB- Paratcha et al. , 2003 -RRB-	5465
@VP	expressing brain-derived neurotrophic factor	5600
@VP	stimulating axonal growth in these cells -LRB- Paratcha et al. , 2003 -RRB-	5776
@VP	applied into the spinal cord	6005
@VP	exert a trophic effect on corticospinal neurons	6052
@VP	promote longterm survival after axotomy -LRB- Giehl et al. , 1997 -RRB-	6104
@VP	can be used to deliver neurotrophic factors to the lesion site	6335
@VP	be used to deliver neurotrophic factors to the lesion site	6339
@VP	used to deliver neurotrophic factors to the lesion site	6342
@VP	to deliver neurotrophic factors to the lesion site	6347
@VP	deliver neurotrophic factors to the lesion site	6350
@VP	do not achieve long-term , localized , high-dose neurotrophic factor delivery	6422
@VP	achieve long-term , localized , high-dose neurotrophic factor delivery	6429
@VP	is ex vivo gene therapy -LRB- Tuszynski , 1997 -RRB-	6625
@VP	to express neurotrophic factors	6747
@VP	express neurotrophic factors	6750
@VP	described increased sprouting of various axonal populations	6947
@VP	increased sprouting of various axonal populations	6957
@VP	sprouting of various axonal populations	6967
@VP	were rerouted around the transplant	7062
@VP	rerouted around the transplant	7067
@VP	were seen distal to the site of injury	7113
@VP	seen distal to the site of injury	7118
@VP	are non-CNS in origin and may become tumorigenic	7435
@VP	are non-CNS in origin	7435
@VP	may become tumorigenic	7461
@VP	become tumorigenic	7465
@VP	transplanting genetically modified OECs into the intact and injured spinal cord	7504
@VP	described by Ruitenberg and colleagues -LRB- Ruitenberg et al. , 2002 -RRB-	7600
@VP	having them secrete additional neurotrophic factors	7732
@VP	secrete additional neurotrophic factors	7744
@VP	has been reported	7944
@VP	been reported	7948
@VP	reported	7953
@VP	ed OECs to secrete a high level of GDNF in order to promote spinal cord repair	8072
@VP	to secrete a high level of GDNF in order to promote spinal cord repair	8080
@VP	secrete a high level of GDNF in order to promote spinal cord repair	8083
@VP	to promote spinal cord repair	8121
@VP	promote spinal cord repair	8124
@VP	was transduced into OECs using a retroviral system	8166
@VP	transduced into OECs using a retroviral system	8170
@VP	using a retroviral system	8191
@VP	to express and secrete biologically active GDNF in vitro	8279
@VP	express and secrete biologically active GDNF in vitro	8282
@VP	express	8282
@VP	secrete biologically active GDNF in vitro	8294
@VP	were examined	8463
@VP	examined	8468
@VP	were assessed	8513
@VP	assessed	8518
@VP	was evaluated at the morphological level	8550
@VP	evaluated at the morphological level	8554
@VP	producing GDNF in vivo to significantly improve recovery after SCI	8689
@VP	to significantly improve recovery after SCI	8712
@VP	significantly improve recovery after SCI	8715
@VP	were set up from adult Sprague ± Dawley rats	8853
@VP	set up from adult Sprague ± Dawley rats	8858
@VP	was used	8995
@VP	used	8999
@VP	was peeled away from the rest of the olfactory bulb	9039
@VP	peeled away from the rest of the olfactory bulb	9043
@VP	then dissociated with 0.25 % trypsin and 0.03 % collagenase	9092
@VP	incubated at 37 °C for 30 min	9154
@VP	washed with D/F12 ± 10 % fetal bovine serum	9204
@VP	scattered and plated on uncoated dishes twice	9249
@VP	was collected	9348
@VP	collected	9352
@VP	was plated on 100 mm Petri dishes for 45 min at 37 °C in 5 % CO2	9401
@VP	plated on 100 mm Petri dishes for 45 min at 37 °C in 5 % CO2	9405
@VP	was used to wash the dishes after each step	9732
@VP	used to wash the dishes after each step	9736
@VP	to wash the dishes after each step	9741
@VP	wash the dishes after each step	9744
@VP	were washed off	9791
@VP	washed off	9796
@VP	were collected using a cell scraper	9830
@VP	collected using a cell scraper	9835
@VP	using a cell scraper	9845
@VP	asks	9917
@VP	containing as mitogen 2 µM forskolin	9971
@VP	cultured OECs	10074
@VP	encoding rat preproGDNF	10278
@VP	was isolated by using the RTPCR method with total RNA extracted from rat brain	10302
@VP	isolated by using the RTPCR method with total RNA extracted from rat brain	10306
@VP	using the RTPCR method with total RNA extracted from rat brain	10318
@VP	extracted from rat brain	10356
@VP	` - GAGGATCCTCAGATACATCCACACC-3	10454
@VP	were designed to amplify preproGDNF cDNA that yielded 652 bp amplified products	10495
@VP	designed to amplify preproGDNF cDNA that yielded 652 bp amplified products	10500
@VP	to amplify preproGDNF cDNA that yielded 652 bp amplified products	10509
@VP	amplify preproGDNF cDNA that yielded 652 bp amplified products	10512
@VP	yielded 652 bp amplified products	10541
@VP	amplified products	10556
@VP	shown in Fig. 1	10787
@VP	is capable of duplication and transfer to the 5 `	10902
@VP	can improve the expression of	10980
@VP	improve the expression of	10984
@VP	transduced genes	11010
@VP	was confirmed by restriction analysis and sequencing	11042
@VP	confirmed by restriction analysis and sequencing	11046
@VP	was used to isolate resistant colonies	11247
@VP	used to isolate resistant colonies	11251
@VP	to isolate resistant colonies	11256
@VP	isolate resistant colonies	11259
@VP	described previously	11358
@VP	was used to infect the purified adult rat primary OECs	11491
@VP	used to infect the purified adult rat primary OECs	11495
@VP	to infect the purified adult rat primary OECs	11500
@VP	infect the purified adult rat primary OECs	11503
@VP	infect the purified adult rat	11503
@VP	infecting dividing OECs	11577
@VP	dividing OECs	11587
@VP	containing mitogens	11721
@VP	was repeated the next day	11761
@VP	repeated the next day	11765
@VP	was added for only l h.	11802
@VP	added for only l h.	11806
@VP	were selected with 200 mg/ml G418	11879
@VP	selected with 200 mg/ml G418	11884
@VP	had grown in a stable manner	11943
@VP	grown in a stable manner	11947
@VP	to produce enough OECs for experiments	12087
@VP	produce enough OECs for experiments	12090
@VP	were fixed for 10 min with 4 % paraformaldehyde	12213
@VP	fixed for 10 min with 4 % paraformaldehyde	12218
@VP	washing in PBS and blocking with 1 % bovine serum albumin for 30 min	12267
@VP	washing in PBS	12267
@VP	blocking with 1 % bovine serum albumin for 30 min	12286
@VP	diluted in PBS containing 1 % bovine serum albumin	12644
@VP	containing 1 % bovine serum albumin	12659
@VP	washed in PBS	12732
@VP	were then washed and examined with an Olympus BX-50 ¯ uorescence microscope	12861
@VP	washed and examined with an Olympus BX-50 ¯ uorescence microscope	12871
@VP	secreted by GDNF OECs	12981
@VP	using the GDNF Emax ImmunoAssay System -LRB- Promega -RRB-	13061
@VP	were then blocked for 1 h at room temperature with blocking buffer	13271
@VP	blocked for 1 h at room temperature with blocking buffer	13281
@VP	blocking buffer	13322
@VP	ranging from 0 to 1000 pg/ml	13354
@VP	were prepared using recombinant GDNF	13383
@VP	prepared using recombinant GDNF	13388
@VP	using recombinant GDNF	13397
@VP	obtained using 2 x 106 cells in 2 ml medium	13449
@VP	using 2 x 106 cells in 2 ml medium	13458
@VP	with only 1 % fetal bovine serum for 24 h	13498
@VP	then added to the wells -LRB- 100 µl -RRB- undiluted or diluted	13540
@VP	were incubated at room temperature for 6 h on a shaker	13635
@VP	incubated at room temperature for 6 h on a shaker	13640
@VP	was used to wash the plates after each step	13983
@VP	used to wash the plates after each step	13987
@VP	to wash the plates after each step	13992
@VP	wash the plates after each step	13995
@VP	was stopped by adding 100 ml of 1 M phosphoric acid per well	14048
@VP	stopped by adding 100 ml of 1 M phosphoric acid per well	14052
@VP	adding 100 ml of 1 M phosphoric acid per well	14063
@VP	was measured at 450 nm	14128
@VP	measured at 450 nm	14132
@VP	were calculated from the standard curve in the linear range	14166
@VP	calculated from the standard curve in the linear range	14171
@VP	secreted GDNF	14258
@VP	expresses GDNF receptor GFRa1 and Ret -LRB- Chen et al. , 2001 -RRB-	14320
@VP	had been coated with poly-L-lysine	14472
@VP	been coated with poly-L-lysine	14476
@VP	coated with poly-L-lysine	14481
@VP	were exposed to CM from OECs or GDNF OECs	14536
@VP	exposed to CM from OECs or GDNF OECs	14541
@VP	was used as negative control	14583
@VP	used as negative control	14587
@VP	was the positive control	14631
@VP	was prepared as previously described -LRB- Chen et al. , 2000 -RRB-	14662
@VP	prepared as previously described -LRB- Chen et al. , 2000 -RRB-	14666
@VP	described	14689
@VP	was determined	14780
@VP	determined	14784
@VP	were scored as positive	14892
@VP	scored as positive	14897
@VP	is the mean ± SEM sampled from three independent experiments	14928
@VP	sampled from three independent experiments	14946
@VP	reached con ¯ uence , monolayers of purified OECs or GDNF OECs	15027
@VP	were trypsinized and collected for transplantation	15269
@VP	trypsinized and collected for transplantation	15274
@VP	followed recommended NIH guidelines	15361
@VP	followed by a transection at T8 using microscissors	15586
@VP	using microscissors	15618
@VP	was carefully lifted up , allowing veri ® cation of complete transection	15656
@VP	lifted up , allowing veri ® cation of complete transection	15670
@VP	allowing veri ® cation of complete transection	15681
@VP	using sterile glass needles	15950
@VP	were operated	16000
@VP	operated	16005
@VP	received a transection with no grafted OECs	16033
@VP	received 0.5 µl DMEM	16092
@VP	receiving 0.5 µl OEC suspension containing about 50 000 cells	16165
@VP	containing about 50 000 cells	16197
@VP	receiving 0.5 µl cell suspension containing about 50 000 cells	16282
@VP	containing about 50 000 cells	16315
@VP	injected with cefazolin sodium -LRB- 40 mg/day -RRB- for up to 1 week	16418
@VP	received bladder expression twice daily until normal function returned	16483
@VP	returned	16545
@VP	was collected	16734
@VP	collected	16738
@VP	was isolated from the tissue using TRIzol -LRB- Gibco BRL -RRB-	16759
@VP	isolated from the tissue using TRIzol -LRB- Gibco BRL -RRB-	16763
@VP	using TRIzol -LRB- Gibco BRL -RRB-	16788
@VP	was measured photometrically	16839
@VP	measured photometrically	16843
@VP	were digested with RNase-free DNase I	16903
@VP	digested with RNase-free DNase I	16908
@VP	was synthesized using a Dmniscript TM PT kit -LRB- Qiagen -RRB-	16951
@VP	synthesized using a Dmniscript TM PT kit -LRB- Qiagen -RRB-	16955
@VP	using a Dmniscript TM PT kit -LRB- Qiagen -RRB-	16967
@VP	- AATATGCCCGAAGATTATCC-3 ` ; reverse , 5 ` - GTTTAGCGGAATGCTTTCTT-3 `	17044
@VP	` - GTTTAGCGGAATGCTTTCTT-3	17080
@VP	were designed to amplify GDNF cDNA to yield 466 bp amplified products	17107
@VP	designed to amplify GDNF cDNA to yield 466 bp amplified products	17112
@VP	to amplify GDNF cDNA to yield 466 bp amplified products	17121
@VP	amplify GDNF cDNA to yield 466 bp amplified products	17124
@VP	to yield 466 bp amplified products	17142
@VP	yield 466 bp amplified products	17145
@VP	amplified products	17158
@VP	was co-amplified with GDNF	17298
@VP	co-amplified with GDNF	17302
@VP	followed by annealing at 55 °C for 1 min and DNA extension at 72 °C for 1 min	17501
@VP	were electrophoresed on 1.5 % agarose gel	17610
@VP	electrophoresed on 1.5 % agarose gel	17615
@VP	were stained with ethidium bromide and photographed under ultraviolet light	17657
@VP	stained with ethidium bromide and photographed under ultraviolet light	17662
@VP	stained with ethidium bromide	17662
@VP	photographed under ultraviolet light	17696
@VP	tracing with HRP Twelve animals	17745
@VP	were used for HRP retrograde tracing	17845
@VP	used for HRP retrograde tracing	17850
@VP	tracing	17874
@VP	to avoid diffusion of HRP into the transplant	18068
@VP	avoid diffusion of HRP into the transplant	18071
@VP	was closed	18154
@VP	closed	18158
@VP	being perfused by buffered 1 % paraformaldehyde and 1.25 % glutaraldehyde	18213
@VP	perfused by buffered 1 % paraformaldehyde and 1.25 % glutaraldehyde	18219
@VP	buffered 1 % paraformaldehyde and 1.25 % glutaraldehyde	18231
@VP	were removed and stored in 20 % sucrose in 0.1 M PBS at 4 °C overnight	18312
@VP	removed and stored in 20 % sucrose in 0.1 M PBS at 4 °C overnight	18317
@VP	were cut transversely and serially at 30 µm	18494
@VP	cut transversely and serially at 30 µm	18499
@VP	cut transversely	18499
@VP	serially at 30 µm	18520
@VP	counterstaining with neutral red	18728
@VP	were observed under a light microscope	18775
@VP	observed under a light microscope	18780
@VP	was con ® ned	18921
@VP	ned	18929
@VP	was no spread of dye to the transplant	18948
@VP	dye to the transplant	18965
@VP	did not measure up to this criterion	19001
@VP	measure up to this criterion	19009
@VP	were eliminated from the study	19038
@VP	eliminated from the study	19043
@VP	could be observed	19242
@VP	be observed	19248
@VP	observed	19251
@VP	was designated as the first section for analysis	19260
@VP	designated as the first section for analysis	19264
@VP	using a digitizing tablet and PC-based software -LRB- Metamorph -RRB-	19460
@VP	was an HRP-filled pyramidal shape > 4 mm in diameter	19545
@VP	were counted	19655
@VP	counted	19660
@VP	biotinylated dextran amine Antegrade tracing of CST fibres from the motor cortex	19692
@VP	tracing of CST fibres from the motor cortex	19729
@VP	was performed following Ramon-Cueto et al. -LRB- 2000 -RRB-	19773
@VP	performed following Ramon-Cueto et al. -LRB- 2000 -RRB-	19777
@VP	were drilled in the cranium to expose both sensorimotor cortices	19872
@VP	drilled in the cranium to expose both sensorimotor cortices	19877
@VP	to expose both sensorimotor cortices	19900
@VP	expose both sensorimotor cortices	19903
@VP	to cover the entire hindlimb region	20114
@VP	cover the entire hindlimb region	20117
@VP	were killed	20177
@VP	killed	20182
@VP	to visualize BDA-containing corticospinal axons	20263
@VP	visualize BDA-containing corticospinal axons	20266
@VP	To quantify CST fibres	20312
@VP	quantify CST fibres	20315
@VP	followed a method described previously -LRB- Blits et al. , 2000 -RRB-	20338
@VP	described previously	20356
@VP	To quantify the number of CST fibres in the animals that survived for 8 weeks	20399
@VP	quantify the number of CST fibres in the animals that survived for 8 weeks	20402
@VP	survived for 8 weeks	20456
@VP	was identified microscopically and determined as point 0	20543
@VP	identified microscopically and determined as point 0	20547
@VP	identified microscopically	20547
@VP	determined as point 0	20578
@VP	were perfused with 4 % paraformaldehyde in 0.1 M ice-cold phosphate buffer	20769
@VP	perfused with 4 % paraformaldehyde in 0.1 M ice-cold phosphate buffer	20774
@VP	removed	20864
@VP	postfixed for 5 h	20873
@VP	placed in 30 % sucrose/PBS before preparing 30 mm sagittal cryosections	20895
@VP	preparing 30 mm sagittal cryosections	20928
@VP	equipped with a 365 nm excitation filter and a 420 nm emission filter	21034
@VP	were permeabilized	21137
@VP	blocked with 0.3 % Triton X-100 / 10 % normal goat serum in 0.1 M PBS for 15 min	21160
@VP	were then applied to the sections overnight at 4 °C	21257
@VP	applied to the sections overnight at 4 °C	21267
@VP	were washed , mounted , and examined by Olympus ¯ uorescent microscopy	21619
@VP	washed , mounted , and examined by Olympus ¯ uorescent microscopy	21624
@VP	washed	21624
@VP	mounted	21632
@VP	examined by Olympus ¯	21645
@VP	determined in 3 mm wide strips of spinal tissue through the lesion centre	21746
@VP	were viewed and photographed with an Olympus photo microscope -LRB- BX70 -RRB-	21828
@VP	viewed and photographed with an Olympus photo microscope -LRB- BX70 -RRB-	21833
@VP	were automatically detected	22067
@VP	automatically detected	22072
@VP	were obtained	22157
@VP	obtained	22162
@VP	was performed	22196
@VP	performed	22200
@VP	was evaluated using the open-field walking scoring system	22368
@VP	evaluated using the open-field walking scoring system	22372
@VP	using the open-field walking scoring system	22382
@VP	to complete mobility	22762
@VP	complete mobility	22765
@VP	were subjected to an inclined plane test -LRB- Rivlin and Tator , 1977 -RRB-	22833
@VP	subjected to an inclined plane test -LRB- Rivlin and Tator , 1977 -RRB-	22838
@VP	could maintain a stable position for 5 s on the inclined plane	22938
@VP	maintain a stable position for 5 s on the inclined plane	22944
@VP	was recorded	23001
@VP	recorded	23005
@VP	contains a GDNF gene in the U3 region of the 3 ` - LTR	23293
@VP	is a G418/neomycin resistant gene	23353
@VP	could be duplicated	23458
@VP	be duplicated	23464
@VP	transferred to the 5 ` - LTR -LRB- asterisk -RRB-	23482
@VP	eliminating	23595
@VP	at least reducing the negative effects of the retroviral transcriptional unit	23610
@VP	weakly staining for GFAP	24019
@VP	did not express p75NGFR	24088
@VP	express p75NGFR	24096
@VP	were probably astrocytes -LRB- arrow in C -RRB-	24112
@VP	was much stronger in astrocytes than in OECs	24167
@VP	was much stronger in GDNF OECs -LRB- E -RRB- than in normal OECs -LRB- F -RRB-	24237
@VP	bar = 100 µm	24303
@VP	= 100 µm	24307
@VP	can be viewed in colour as supplementary material at Brain Online	24329
@VP	be viewed in colour as supplementary material at Brain Online	24333
@VP	viewed in colour as supplementary material at Brain Online	24336
@VP	obtained using the GDNF Emax ImmunoAssay System	24505
@VP	using the GDNF Emax ImmunoAssay System	24514
@VP	comparing ex vivo GDNF secretion between normal OECs and GDNF OEC groups	24568
@VP	produced an average of 25 ng GDNF/106 cells/24 h.	24731
@VP	h.	24778
@VP	comparing differentiation ratios of PC12-GFRa1	24834
@VP	obtained from GDNF OECs or uninfected OECs	24992
@VP	was detected 8 weeks after operation by RT-PCR analysis	25147
@VP	detected 8 weeks after operation by RT-PCR analysis	25151
@VP	is around 460 bp	25283
@VP	is around 100 bp	25327
@VP	injected with GDNF OECs	25353
@VP	was dramatically increased	25421
@VP	dramatically increased	25425
@VP	infected with the recombinant retrovirus containing GFP	25525
@VP	containing GFP	25566
@VP	implanted in the lesion of the spinal cord	25585
@VP	shows the magnified image	25880
@VP	are immunoreactive for p75 NGFR -LRB- blue -RRB-	25934
@VP	have invaded the spinal cord , as suggested by Ruitenberg et al.	26079
@VP	invaded the spinal cord , as suggested by Ruitenberg et al.	26084
@VP	invaded the spinal cord	26084
@VP	suggested by Ruitenberg	26112
@VP	bar = 150 µm	26157
@VP	= 150 µm	26161
@VP	can be viewed in colour as supplementary material at Brain Online	26183
@VP	be viewed in colour as supplementary material at Brain Online	26187
@VP	viewed in colour as supplementary material at Brain Online	26190
@VP	shows glial scar -LRB- arrow -RRB- in spinal cord lesion	26600
@VP	outlined in C	26716
@VP	displayed mostly scattered profiles , and many NFimmunoreactive fibres	26731
@VP	were stopped at the host ± scar interface -LRB- arrows -RRB-	26801
@VP	stopped at the host ± scar interface -LRB- arrows -RRB-	26806
@VP	-LRB- E , F -RRB- In the normal OEC group	26851
@VP	elongated NF-positive axons -LRB- arrows -RRB-	26883
@VP	were present throughout the lesion -LRB- outlined in E -RRB-	26920
@VP	outlined in E	26956
@VP	was found in the lesion site -LRB- outlined in G -RRB- ; some of them	27064
@VP	found in the lesion site -LRB- outlined in G -RRB- ; some of them	27068
@VP	outlined in G	27094
@VP	were derived from the invaded dorsal root -LRB- asterisk -RRB-	27123
@VP	derived from the invaded dorsal root -LRB- asterisk -RRB-	27128
@VP	had a variety of orientations	27234
@VP	can be viewed in colour as supplementary material at Brain Online	27333
@VP	be viewed in colour as supplementary material at Brain Online	27337
@VP	viewed in colour as supplementary material at Brain Online	27340
@VP	sprouting through the lesion centre	27466
@VP	Implanted	27545
@VP	are indicated by Hoechst -LRB- blue -RRB- / p75NGFR -LRB- red -RRB- labelling	27560
@VP	indicated by Hoechst -LRB- blue -RRB- / p75NGFR -LRB- red -RRB- labelling	27564
@VP	were often found in bundles -LRB- arrowhead -RRB-	27822
@VP	found in bundles -LRB- arrowhead -RRB-	27833
@VP	bar = 20 µm	27869
@VP	= 20 µm	27873
@VP	receiving GDNF OECs than in those receiving normal OECs -LRB- P < 0.01 -RRB-	28049
@VP	receiving normal OECs -LRB- P < 0.01 -RRB-	28083
@VP	receiving OECs	28154
@VP	receiving DMEM	28183
@VP	followed by least significant difference test , n = 5	28269
@VP	can be viewed in colour as supplementary material at Brain Online	28335
@VP	be viewed in colour as supplementary material at Brain Online	28339
@VP	viewed in colour as supplementary material at Brain Online	28342
@VP	are HRP-positive	28565
@VP	Sham-operated animal	28590
@VP	DMEM group	28619
@VP	OEC group	28638
@VP	were observed in the CSN or RSN	28726
@VP	observed in the CSN or RSN	28731
@VP	receiving OECs only	28770
@VP	were observed	28812
@VP	observed	28817
@VP	were found in the GDNF OEC group	28857
@VP	found in the GDNF OEC group	28862
@VP	bar = 200 µm	28897
@VP	= 200 µm	28901
@VP	can be viewed in colour as supplementary material at Brain Online	28923
@VP	be viewed in colour as supplementary material at Brain Online	28927
@VP	viewed in colour as supplementary material at Brain Online	28930
@VP	receiving GDNF OECs	29111
@VP	labelled than in those receiving normal OECs -LRB- P < 0.01 -RRB-	29174
@VP	receiving normal OECs -LRB- P < 0.01 -RRB-	29197
@VP	receiving OECs than in those receiving DMEM -LRB- P < 0.01 -RRB-	29273
@VP	receiving DMEM -LRB- P < 0.01 -RRB-	29302
@VP	followed by the least significant difference test , n = 3 ± 5	29399
@VP	containing the rostral part of the injury region	29587
@VP	shown in C , F and I	29665
@VP	are represented -LRB- box -RRB-	29685
@VP	represented -LRB- box -RRB-	29689
@VP	containing the caudal part of the injury region	29780
@VP	shown in E , H and K	29857
@VP	are represented -LRB- box -RRB-	29877
@VP	represented -LRB- box -RRB-	29881
@VP	-LRB- C , D , E -RRB- In the control group	29912
@VP	showed little regeneration response at the rostral end	29963
@VP	to grow through the lesion and to reach the segment distal to the lesion centre	30041
@VP	to grow through the lesion	30041
@VP	grow through the lesion	30044
@VP	to reach the segment distal to the lesion centre	30072
@VP	reach the segment distal to the lesion centre	30075
@VP	were found to have formed termination bulbs and some fibres	30167
@VP	found to have formed termination bulbs and some fibres	30172
@VP	to have formed termination bulbs and some fibres	30178
@VP	have formed termination bulbs and some fibres	30181
@VP	formed termination bulbs and some fibres	30186
@VP	had grown through the lesion and reached the segment distal to the lesion centre	30227
@VP	had grown through the lesion	30227
@VP	grown through the lesion	30231
@VP	reached the segment distal to the lesion centre	30260
@VP	-LRB- I , J , K -RRB- In the GDNF OEC group	30309
@VP	were observed	30398
@VP	observed	30403
@VP	were seen at the caudal end of the lesion	30441
@VP	seen at the caudal end of the lesion	30446
@VP	can be viewed in colour as supplementary material at Brain Online	30564
@VP	be viewed in colour as supplementary material at Brain Online	30568
@VP	viewed in colour as supplementary material at Brain Online	30571
@VP	actual tracing efficiency by the cortical BDA injections	30796
@VP	was set to 100 %	30925
@VP	set to 100 %	30929
@VP	were calculated as relative percentages	30954
@VP	calculated as relative percentages	30959
@VP	were observed in the distal spinal cord	31032
@VP	observed in the distal spinal cord	31037
@VP	had grown through the lesion and reached the segment distal to the lesion centre	31115
@VP	had grown through the lesion	31115
@VP	grown through the lesion	31119
@VP	reached the segment distal to the lesion centre	31148
@VP	was found in the segment near the injury side	31247
@VP	found in the segment near the injury side	31251
@VP	followed by least significant difference test , n = 5	31386
@VP	followed by least significant difference test , n = 8 ± 18	31706
@VP	displayed S-100 immunoreactivity	32015
@VP	demonstrated that the purity of GDNF OECs was more than 92 %	32091
@VP	was more than 92 %	32133
@VP	using a viral vector-mediated gene transfer	32202
@VP	did not interfere with normal cell functioning	32246
@VP	interfere with normal cell functioning	32254
@VP	shown in Fig. 2C and D	32477
@VP	having intensive immunostaining for p75 NGFR and weak immunostaining for GFAP	32533
@VP	did not express p75NGFR	32655
@VP	express p75NGFR	32663
@VP	was much stronger than that in OECs	32738
@VP	expected	32778
@VP	was much stronger in GDNF OECs than in normal OECs -LRB- Fig. 2E and F -RRB-	32814
@VP	secreted by GDNF OECs	32946
@VP	was determined by ELISA with detection sensitivity to 31.2 pg / ml of GDNF	32968
@VP	determined by ELISA with detection sensitivity to 31.2 pg / ml of GDNF	32972
@VP	produced an average of 25 ng GDNF/106 cells/day -LRB- Fig. 3 -RRB-	33141
@VP	secreted GDNF	33230
@VP	was examined using PC12-GFRa-Ret cells	33244
@VP	examined using PC12-GFRa-Ret cells	33248
@VP	using PC12-GFRa-Ret cells	33257
@VP	differentiated	33351
@VP	was six-fold greater than that of normal OECs -LRB- Fig. 4 -RRB-	33419
@VP	secreted from GDNF OECs	33509
@VP	promoting PC12 - GFRa-Ret cell differentiation	33572
@VP	to measure the mRNA level of GDNF in the injured spinal cord -LRB- Fig. 5 -RRB-	33707
@VP	measure the mRNA level of GDNF in the injured spinal cord -LRB- Fig. 5 -RRB-	33710
@VP	injected with GDNF OECs	33801
@VP	detected compared with that in the spinal cord of rats injected with normal OECs	33883
@VP	injected with normal OECs	33938
@VP	then implanted in the lesion of spinal cord	34331
@VP	shown in Fig. 6 , 2 months after implantation	34379
@VP	elongated	34478
@VP	extending from the lesion site	34515
@VP	were immunoreactive for p75NGFR	34573
@VP	surviving in the injured spinal cord for at least 2 months after implantation	34670
@VP	was surrounded by an intensively GFAPpositive border of reactive astrocytes	34797
@VP	surrounded by an intensively GFAPpositive border of reactive astrocytes	34801
@VP	could not find OECs across the astrocytic barrier into the spinal cord	34877
@VP	find OECs across the astrocytic barrier into the spinal cord	34887
@VP	were found in the central scar	35374
@VP	found in the central scar	35379
@VP	were stopped at the host ± scar interface -LRB- Fig. 7C and D -RRB-	35439
@VP	stopped at the host ± scar interface -LRB- Fig. 7C and D -RRB-	35444
@VP	shown in Fig. 7E and F	35499
@VP	elongated	35523
@VP	are present throughout the lesion in normal OEC group	35551
@VP	were found in the lesion site in the GDNF OEC group	35659
@VP	found in the lesion site in the GDNF OEC group	35664
@VP	were derived from the invaded dorsal root -LRB- Fig. 7G and H -RRB-	35729
@VP	derived from the invaded dorsal root -LRB- Fig. 7G and H -RRB-	35734
@VP	were often found in bundles	35991
@VP	found in bundles	36002
@VP	receiving GDNF OECs than in those receiving normal OECs	36115
@VP	receiving normal OECs	36149
@VP	labelling after injections of HRP into the low thoracic and upper lumbar region	36199
@VP	labelled RSN	36321
@VP	were smaller than in the RSN	36487
@VP	shown in Fig. 10	36520
@VP	were counted in all groups of animals	36577
@VP	counted in all groups of animals	36582
@VP	were labelled on both sides of the RSN and CSN , respectively	36670
@VP	labelled on both sides of the RSN and CSN , respectively	36675
@VP	were detected in the DMEM group	36788
@VP	detected in the DMEM group	36793
@VP	labelled with HRP	36884
@VP	were detected	36902
@VP	detected	36907
@VP	to regenerate into the caudal spinal cord -LRB- P < 0.01 versus DMEM group -RRB-	37034
@VP	regenerate into the caudal spinal cord -LRB- P < 0.01 versus DMEM group -RRB-	37037
@VP	were labelled with HRP	37203
@VP	labelled with HRP	37208
@VP	To further confirm the axonal regeneration	37317
@VP	further confirm the axonal regeneration	37320
@VP	tracing experiments	37371
@VP	were performed	37391
@VP	performed	37396
@VP	showed little regeneration response in the segment rostral to the lesion centre	37544
@VP	were found to have formed termination bulbs	37675
@VP	found to have formed termination bulbs	37680
@VP	to have formed termination bulbs	37686
@VP	have formed termination bulbs	37689
@VP	formed termination bulbs	37694
@VP	had grown through the lesion and reached the segment distal to the lesion centre	37735
@VP	had grown through the lesion	37735
@VP	grown through the lesion	37739
@VP	reached the segment distal to the lesion centre	37768
@VP	were found in the segment near the injury side in the GDNF OEC group	37880
@VP	found in the segment near the injury side in the GDNF OEC group	37885
@VP	were found between the OEC and GDNF OEC groups -LRB- Fig. 12 -RRB-	38048
@VP	found between the OEC and GDNF OEC groups -LRB- Fig. 12 -RRB-	38053
@VP	manifested complete hind limb paralysis immediately after injury	38249
@VP	were in the range of 0 ± 2 in the control animals	38330
@VP	increased gradually	38448
@VP	achieved by any of the eight	38554
@VP	could support their body weight on their hind limbs	38659
@VP	support their body weight on their hind limbs	38665
@VP	had ankle , knee and hip movements in one or both legs	38733
@VP	did not obviously bear weight	38791
@VP	obviously bear weight	38799
@VP	treated with GDNF OECs	38961
@VP	could walk in a coordinated manner	38984
@VP	walk in a coordinated manner	38990
@VP	were also significant	39091
@VP	had a higher score than those in the OEC group -LRB- P < 0.05 -RRB-	39312
@VP	is perhaps one of the most powerful strategies to promote CNS repair	39426
@VP	to promote CNS repair	39473
@VP	promote CNS repair	39476
@VP	upgrading OECs to enhance the regenerative properties of these cells	39714
@VP	to enhance the regenerative properties of these cells	39729
@VP	enhance the regenerative properties of these cells	39732
@VP	tracing experiments -LRB- Ruitenberg et al. , 2002 -RRB-	39869
@VP	were genetically modified to overexpress exogenous neurotrophic factor	40058
@VP	to overexpress exogenous neurotrophic factor	40084
@VP	overexpress exogenous neurotrophic factor	40087
@VP	were transplanted into the transected spinal cord	40133
@VP	transplanted into the transected spinal cord	40138
@VP	have been widely used for gene transfer	40360
@VP	been widely used for gene transfer	40365
@VP	widely used for gene transfer	40370
@VP	integrate with high efficiency	40414
@VP	mediate long-term expression	40484
@VP	avoid host cellular immune responses -LRB- Robbins et al. , 1998 -RRB-	40517
@VP	could be detected even 2 months after implantation	40636
@VP	be detected even 2 months after implantation	40642
@VP	detected even 2 months after implantation	40645
@VP	Tracing the GFP OECs confirmed that the implanted	40688
@VP	confirmed that the implanted	40709
@VP	implanted	40728
@VP	surviving and expressing the foreign gene in the spinal cord lesion	40781
@VP	may interfere with the expression of various gene cassettes	41169
@VP	interfere with the expression of various gene cassettes	41173
@VP	were detected after transduction of OECs by retroviral vectors in this study	41302
@VP	detected after transduction of OECs by retroviral vectors in this study	41307
@VP	transduced OECs into the site of a spinal cord lesion	41425
@VP	were p75NGFR-positive and displayed	41479
@VP	were p75NGFR-positive	41479
@VP	displayed	41505
@VP	did not interfere with normal cell functioning	41607
@VP	interfere with normal cell functioning	41615
@VP	strongly supports the survival of motoneurons both in vitro	41847
@VP	applied into the spinal cord	42031
@VP	exerts a trophic effect on corticospinal neurons	42066
@VP	promotes their long-term survival after axotomy -LRB- Giehl et al. , 1997 -RRB-	42119
@VP	had indeed regenerated through the transection site	42526
@VP	regenerated through the transection site	42537
@VP	were detected 8 weeks after SCI in the GDNF OEC group	42609
@VP	detected 8 weeks after SCI in the GDNF OEC group	42614
@VP	were detected	42741
@VP	detected	42746
@VP	tracing experiments	42770
@VP	confirmed that more CST fibres had grown through the lesion	42790
@VP	had grown through the lesion	42821
@VP	grown through the lesion	42825
@VP	might enhance the growth-promoting properties of OECs after SCI	43130
@VP	enhance the growth-promoting properties of OECs after SCI	43136
@VP	are several possible explanations for this phenomenon	43201
@VP	cultured OECs	43600
@VP	express GDNF receptor GFRa1 -LRB- Woodhall et al. , 2001 -RRB-	43614
@VP	secreted from GDNF OECs	43698
@VP	may have trophic effects on themselves	43722
@VP	have trophic effects on themselves	43726
@VP	were evaluated using the inclined plane method of Rivlin and BBB scale	43797
@VP	evaluated using the inclined plane method of Rivlin and BBB scale	43802
@VP	using the inclined plane method of Rivlin and BBB scale	43812
@VP	differs from other locomotor scoring systems in several respects	43892
@VP	is not a summation of component behaviours	43975
@VP	requires fulfilment of a unique set of criteria	44034
@VP	encompass many behavioural traits	44104
@VP	represent a detailed characterization of rat locomotor function	44142
@VP	are based on observations of rat recovery from SCI	44227
@VP	based on observations of rat recovery from SCI	44231
@VP	assumes progressive recovery	44306
@VP	Using the BBB scale and the inclined plane method	44440
@VP	demonstrated a progressive recovery over time among three groups	44494
@VP	is in accordance with the morphological experiments	44699
@VP	achieved in the GDNF OEC and normal OEC groups compared with the control group	44809
@VP	tracing results	45090
@VP	had severe tissue loss next to the transection centre	45173
@VP	sparing with higher locomotor scores after SCI	45275
@VP	has been reported previously -LRB- Basso et al. , 1996 -RRB-	45322
@VP	been reported previously -LRB- Basso et al. , 1996 -RRB-	45326
@VP	reported previously -LRB- Basso et al. , 1996 -RRB-	45331
@VP	secreted by the OEC	45575
@VP	to increase tissue sparing in a contusion model -LRB- Cheng et al. , 2002 -RRB-	45672
@VP	increase tissue sparing in a contusion model -LRB- Cheng et al. , 2002 -RRB-	45675
@VP	secreted by the OEC	45760
@VP	were genetically modified to secrete an increased level of GDNF	46070
@VP	to secrete an increased level of GDNF	46096
@VP	secrete an increased level of GDNF	46099
@VP	opens up new possibilities for future clinical applications in SCI	46163
@VP	added in proof	46237
@VP	addresses the point of the effect of genetically modified OECs on tissue sparing	46343
@VP	observed in the present study	46498
@VP	could be partly explained in this way	46528
@VP	be partly explained in this way	46534
@VP	partly explained in this way	46537
@VP	thank Professor Xuan Bao for her helpful suggestions and valuable comments	46588
